fluconazole and Candidemia studies

Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.
fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.

Candidemia: A form of invasive candidiasis where species of CANDIDA are present in the blood.

Research Excerpts

Excerpt	Relevance	Reference
"A secondary analysis of data from a previously published prospective, randomized, double-blind clinical trial was performed; it compared anidulafungin with fluconazole for the treatment of invasive candidiasis and candidemia."	9.15	Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: support for the 2009 IDSA treatment guidelines for candidiasis. ( Biswas, P; Kett, DH; Reboli, AC; Reisman, AL; Schlamm, HT; Shorr, AF, 2011)
"A MEDLINE search of the English language literature was performed using the search terms echinocandin, fluconazole, and candidemia."	8.91	Is Fluconazole or an Echinocandin the Agent of Choice for Candidemia. ( Clancy, CJ; Eschenauer, GA; Nguyen, MH, 2015)
"We introduced the Early Fluconazole Treatment in Candidemia (EFTC) protocol in August 2015 to improve the outcomes of patients with candidemia."	8.02	Evaluation of the early fluconazole treatment of candidemia protocol with automated short message service alerts: a before-and-after study. ( Heo, ST; Jo, S; Shin, BR; Yoo, JR, 2021)
"This study highlights that prophylactic fluconazole may be an associated factor of Malassezia colonization; M furfur remains a potential concern for fungemia in the care of premature infants and thus requires our attention."	7.96	Malassezia furfur Emergence and Candidemia Trends in a Neonatal Intensive Care Unit During 10 Years: The Experience of Fluconazole Prophylaxis in a Single Hospital. ( Chen, CC; Chen, IT; Huang, HC; Kuo, KC, 2020)
"Breakthrough candidemia (BTC) on fluconazole was associated with non-susceptible Candida spp."	7.88	Fluconazole non-susceptible breakthrough candidemia after prolonged low-dose prophylaxis: a prospective FUNGINOS study. ( Bille, J; Bochud, PY; Boggian, K; Bregenzer, T; Bruderer, T; Calandra, T; Conen, A; Damonti, L; Emonet, S; Erard, V; Fehr, J; Flückiger, U; Frei, R; Garbino, J; Imhof, A; Khanna, N; Lamoth, F; Marchetti, O; Mertz, D; Mühlethaler, K; Orasch, C; Ruef, C; Schrenzel, J; van Delden, C; Zbinden, R; Zimmerli, S, 2018)
"Echinocandins were more effective than fluconazole in achieving mycological eradication in patients with persistent candidemia."	7.88	Effectiveness of echinocandins versus fluconazole for treatment of persistent candidemia: A time-dependent analysis. ( Chang, SC; Chen, PY; Chen, YC; Chuang, YC; Lin, KY; Sheng, WH; Sun, HY; Wang, JT, 2018)
"We compared the clinical efficacy of fluconazole and echinocandins in the treatment of candidemia in real practice."	7.83	Empirical and targeted therapy of candidemia with fluconazole versus echinocandins: a propensity score-derived analysis of a population-based, multicentre prospective cohort. ( Almirante, B; Cuenca-Estrella, M; Garnacho-Montero, J; López-Cortés, LE; Padilla, B; Puig-Asensio, M; Rodríguez-Baño, J; Ruiz-Camps, I, 2016)
"Fluconazole-initiated treatment followed by caspofungin was cost-effective for the treatment of IC/C compared to fluconazole with L-AmB as second-line treatment, at US$316/QALY gained."	5.72	Cost-utility analysis of caspofungin and fluconazole for primary treatment of invasive candidiasis and candidemia in Ethiopia. ( Abebe, W; Alemayehu, T; Ali, EE; Erku, DA; Fentie, AM; Gebremariam, GT; Gebretekle, GB; Sander, B, 2022)
"Whether echinocandins could be used to treat candidemia of a urinary tract source (CUTS) is unknown."	5.46	Echinocandins Compared to Fluconazole for Candidemia of a Urinary Tract Source: A Propensity Score Analysis. ( Aguado, JM; Almirante, B; Ayats, J; Blanco-Vidal, MJ; Cardozo, C; Carratalà, J; Cuervo, G; Fernández-Ruiz, M; Garcia-Vidal, C; González-Barberá, E; Gudiol, C; Manzur, A; Marco, F; Meije, Y; Montejo, JM; Muñoz, P; Pemán, J; Puig-Asensio, M; Vena, A, 2017)
"Candidemia is an increasing problem in tertiary care hospitals worldwide."	5.43	Outbreak of candidemia caused by fluconazole resistant Candida parapsilosis strains in an intensive care unit. ( Casulari, LA; Colombo, AL; Damasceno, CM; Pinhati, HM; Siqueira, RA; Souza, AC, 2016)
"The incidence of candidemia has increased over the past two decades, with an increased number of cases in Internal Medicine and a prevalence ranging from 24% to 57%."	5.42	The Effect on mortality of fluconazole or echinocandins treatment in candidemia in internal medicine wards [corrected]. ( Aldieri, C; Cavallo, R; Corcione, S; De Rosa, FG; Di Perri, G; Filippini, C; Fossati, L; Montrucchio, C; Petrolo, A; Raviolo, S, 2015)
"Micafungin (MCFG) alone was ineffective; however, the combination of MCFG with fosfluconazole (F-FLCZ) successfully treated the patient without a need for any anticoagulant or surgical therapies."	5.39	Successful treatment of recurrent candidemia due to candidal thrombophlebitis associated with a central venous catheter using a combination of fosfluconazole and micafungin. ( Hagiya, H; Kajioka, H, 2013)
" Suboptimal initial dosing of prior fluconazole therapy was associated with candidemia with fluconazole-nonsusceptible Candida species."	5.38	Impact of prior inappropriate fluconazole dosing on isolation of fluconazole-nonsusceptible Candida species in hospitalized patients with candidemia. ( Garey, KW; Lasco, TM; Palmer, HR; Salazar, M; Shah, DN; Weston, J; Yau, R, 2012)
"Anidulafungin was effective in the treatment of patients with documented candidemia arising from different sites, and no significant side effects were observed."	5.36	Clinical experience of anidulafungin for the treatment of patients with documented candidemia. ( De Rosa, FG; Falcone, M; Ghezzi, MC; Pasero, D; Raponi, G; Russo, A; Toma, L; Venditti, M, 2010)
" parapsilosis candidemia suggests possible treatment after MALDI-TOF identification with fluconazole as first-line therapy in our hospital, as soon as possible and while continuing to perform the antifungal test."	5.22	Epidemiology of candidemia in NICE area, France: A five-year study of antifungal susceptibility and mortality. ( Emery, S; Gastaud, L; Hasseine, L; Legueult, K; Lieutier-Colas, F; Mondain, V; Pomares, C; Retur, N; Vannini, M, 2022)
"A secondary analysis of data from a previously published prospective, randomized, double-blind clinical trial was performed; it compared anidulafungin with fluconazole for the treatment of invasive candidiasis and candidemia."	5.15	Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: support for the 2009 IDSA treatment guidelines for candidiasis. ( Biswas, P; Kett, DH; Reboli, AC; Reisman, AL; Schlamm, HT; Shorr, AF, 2011)
"Post hoc analysis of patient-level efficacy and safety data from six studies of anidulafungin (with similar protocols/endpoints) in adults with IC/candidemia summarized by past or recent diagnosis of solid tumors."	5.12	Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies. ( Aram, JA; Busca, A; Capparella, MR; De Rosa, FG; Yan, JL, 2021)
"A MEDLINE search of the English language literature was performed using the search terms echinocandin, fluconazole, and candidemia."	4.91	Is Fluconazole or an Echinocandin the Agent of Choice for Candidemia. ( Clancy, CJ; Eschenauer, GA; Nguyen, MH, 2015)
" Since all fluconazole resistance isolates were obtained from candidemia, we recommend amphotericin B as the first line therapy for this potentially fatal infection."	4.31	A 3-year study of ( Abastabar, M; Badiee, P; Haghani, I; Mohammadi, R; Morovati, H; Noorbakhsh, M; Sharifi, M, 2023)
"All persistent candidemia resolved on fluconazole combined with caspofungin therapy."	4.02	Successful fluconazole combined with caspofungin treatment of candida bloodstream infection in preterm infant: A case report. ( Liu, L; Tu, Y; Xu, T; Yuan, G, 2021)
" albicans candidemia, >65 years of age and surgical procedure is associated with significant mortality, however, the use of fluconazole has shown the increased survival rate."	4.02	Epidemiology, risk factors, treatment and outcome of Candida bloodstream infections because of Candida albicans and Candida non-albicans in two district general hospitals in the United Kingdom. ( Raja, NS, 2021)
"A substantial proportion of patients with candidemia were initially treated with fluconazole, resulting in potentially inappropriate treatment for those involving non-albicans or fluconazole-resistant species."	4.02	Treatment Practices for Adults With Candidemia at 9 Active Surveillance Sites-United States, 2017-2018. ( Barter, DM; Czaja, CA; Davis, SS; Farley, MM; Fischer, J; Gold, JAW; Harrison, LH; Jackson, BR; Johnston, H; Lockhart, SR; Lyman, M; Markus, TM; Mody, RK; Nadle, J; Pattee, B; Phipps, EC; Schaffner, W; Seagle, EE; Tesini, BL; Thomas, S; Vallabhaneni, S; Zhang, AY, 2021)
"This study confirms that the use of azoles recommended for candidemia, mostly fluconazole, as a first-line therapy is a reasonable alternative to caspofungin for ICU patients in our institution."	3.96	Evaluation of first-line therapies for the treatment of candidemia in ICU patients: A propensity score analysis. ( Argaud, L; Aubrun, F; Bienvenu, AL; Chidiac, C; Fellahi, JL; Friggeri, A; Guerin, C; Guichon, C; Hernu, R; Leboucher, G; Menotti, J; Monard, C; Paulus, S; Piriou, V; Pradat, P; Rimmele, T, 2020)
"Adults with candidemia caused by LBF and HBF/MBF Candida species that were susceptible to fluconazole and caspofungin were included to investigate the impact of treatment with fluconazole vs an echinocandin on 30-day crude mortality."	3.96	Impact of biofilm production by Candida species and antifungal therapy on mortality of patients with candidemia. ( Chen, FJ; Chen, IL; Chen, YC; Chien, CC; Lee, CH, 2020)
"This study highlights that prophylactic fluconazole may be an associated factor of Malassezia colonization; M furfur remains a potential concern for fungemia in the care of premature infants and thus requires our attention."	3.96	Malassezia furfur Emergence and Candidemia Trends in a Neonatal Intensive Care Unit During 10 Years: The Experience of Fluconazole Prophylaxis in a Single Hospital. ( Chen, CC; Chen, IT; Huang, HC; Kuo, KC, 2020)
"High rates of non-albicans species and fluconazole non-susceptibility must be taken into account to optimize therapeutic management and outcomes in SOT recipients with candidemia."	3.91	Candidemia in solid organ transplant recipients in Spain: Epidemiological trends and determinants of outcome. ( Aguado, JM; Aguilar-Guisado, M; Cardozo, C; Cuervo, G; Escolà-Vergé, L; Fernández-Ruiz, M; García-Vidal, C; Gioia, F; Merino, P; Montejo, M; Muñoz, P; Salavert, M, 2019)
"The objective of this study was to evaluate the impact of echinocandins and fluconazole) on mortality 7 and 30 days after candidemia onset and overall in-hospital mortality), in patients with candidemia at a Spanish tertiary hospital."	3.91	Impact of empirical treatment with antifungal agents on survival of patients with candidemia. ( Alvarez-Fuente, E; Balbás-Alvarez, S; Cano-Hernández, B; de la Varga, O; Eiros, JM; Flores, M; Gómez-Pesquera, E; Gómez-Sánchez, E; Heredia-Rodríguez, M; Lorenzo-López, M; Martínez-Rafael, B; Muñoz-Moreno, MF; Poves-Alvarez, R; Román-García, P; Tamayo, E, 2019)
"The objective of this study was to evaluate the impact of the empirical therapy with fluconazole or an echinocandin on 30- and 90-day mortality in critically ill patients with candidemia."	3.88	Initial Antifungal Strategy Reduces Mortality in Critically Ill Patients With Candidemia: A Propensity Score-Adjusted Analysis of a Multicenter Study. ( Arias-Verdú, D; Cantón-Bulnes, L; Díaz-Martín, A; Estella, Á; García-Garmendia, JL; Garnacho-Montero, J; Gordón, M; Loza-Vázquez, A; Ramírez, P; Rodríguez-Delgado, M; Rodriguez-Gomez, J; Sierra, R, 2018)
" A second opinion at our institute resulted in the diagnosis of hepatic candidiasis without prior documented candidemia, for which she was treated successfully with fluconazole."	3.85	Hepatosplenic Candidiasis Without Prior Documented Candidemia: An Underrecognized Diagnosis? ( Bomers, MK; de Rooij, ML; Meijer, E; Menke-van der Houven van Oordt, CW; van Dijk, K; van Prehn, J, 2017)
" On the basis of antifungal susceptibility profile of the isolates, caspofungin can be suggested as a useful antifungal drug for the treatment of candidemia due to fluconazole resistant species."	3.83	Echinocandin Susceptibility Profile of Fluconazole Resistant Candida Species Isolated from Blood Stream Infections. ( Deorukhkar, SC; Saini, S, 2016)
" Candida albicans has been the species most often associated with neonatal infections, but recently, there has been a changing pattern in the isolates recovered from neonates with invasive candidiasis, which poses resistance to the existing class of azoles such as fluconazole antifungals along with cross resistance to newer triazoles, which results in a therapeutic challenge in invasive fungal infections causing high incidence of mortality."	3.81	Candidemia-induced pediatric sepsis and its association with free radicals, nitric oxide, and cytokine level in host. ( Kumar, A; Kumar, D; Singh, S; Tilak, R, 2015)
" Patients receiving low-dose fluconazole prior to the positive BCx with a known indication for prophylaxis including neutropenia, ICU exposure or history of organ transplantation were classified as prophylaxis."	3.80	Relationship of fluconazole prophylaxis with fungal microbiology in hospitalized intra-abdominal surgery patients: a descriptive cohort study. ( Chaudhari, P; Emons, MF; Khandelwal, N; Shorr, AF; Yu, HT; Zilberberg, M, 2014)
"In a retrospective study (July 2009 to December 2009) on candidemia, various Candida species isolated from blood cultures were characterized and studied along with the determination of their antifungal susceptibility to amphotericin B, itraconazole, and fluconazole by Etest."	3.79	Epidemiology of Candida blood stream infections: experience of a tertiary care centre in North India. ( Chander, J; Gombar, S; Sidhu, SK; Singla, N, 2013)
" As thus system and media are unaffected by added fluconazole, it could be used for the diagnosis of candidemia in the clinical settings including the patients who have been treated empirically with fluconazole at the time when blood cultures were drawn."	3.78	Comparison of the Bactec Fx Plus, Mycosis IC/F, Mycosis/F Lytic blood culture media and the BacT/Alert 3D FA media for detection of Candida species in seeded blood culture specimens containing therapeutic peak levels of fluconazole. ( An, YJ; Baek, SM; Jekarl, DW; Lee, J; Lee, MK; Lee, S; Lee, SY; Ock, SM; Park, YJ, 2012)
"Due to the emergence of drug-resistance, first-line therapy with fluconazole (FLC) increasingly resulted in clinical failure for the treatment of candidemia."	3.78	Calcium-activated-calcineurin reduces the In vitro and In vivo sensitivity of fluconazole to Candida albicans via Rta2p. ( Jia, XM; Jia, Y; Jiang, YY; Tang, RJ; Wang, L; Wang, Y; Zhang, X, 2012)
"IV anidulafungin was effective for the treatment of C."	2.84	Anidulafungin for the treatment of candidaemia caused by Candida parapsilosis: Analysis of pooled data from six prospective clinical studies. ( Aram, J; Bassetti, M; Capparella, MR; Hogan, PA; Kontoyiannis, DP; Nucci, M; Yan, JL, 2017)
"Endophthalmitis is often treated with fluconazole or voriconazole, and the echinocandins are increasingly used, instead of amphotericin B, as initial therapy for osteomyelitis and endocarditis before step-down therapy to oral azole agents."	2.52	Complications of Candidemia in ICU Patients: Endophthalmitis, Osteomyelitis, Endocarditis. ( Kauffman, CA, 2015)
"Fungemia is a serious problem within neonatal intensive care units around the world."	2.50	Fungal prophylaxis in neonates: a review article. ( Bradshaw, WT; Lollis, TR, 2014)
"Fluconazole resistance was present in 16 of 32 cases of C."	2.49	Background changing patterns of neonatal fungal sepsis in a developing country. ( Ballot, DE; Bosman, N; Cooper, PA; Nana, T; Ramdin, T, 2013)
"Candidemia is not confined to hematological patients, intensive care units or abdominal surgery wards, but it is remarkably frequent in the internal medicine setting."	2.48	Occurrence, presentation and treatment of candidemia. ( Del Bono, V; Mikulska, M; Ratto, S; Viscoli, C, 2012)
"Candidemia is a serious condition associated with high morbidity and mortality and increased healthcare costs in pediatric patients."	2.47	Candida infections in non-neutropenic children after the neonatal period. ( Celebi, S; Hacimustafaoglu, M, 2011)
"Candidemia is increasing in frequency and is associated with high mortality."	1.91	Incidence, susceptibility and outcomes of candidemia in adults living in Calgary, Alberta, Canada (2010-2018). ( Barkema, HW; Biesheuvel, MM; Bourassa-Blanchette, S; Carson, J; Church, D; Dalton, B; Gregson, DB; Kipp, A; Lam, JC; Parkins, MD, 2023)
"Candidemia is a serious complication in pediatric patients with congenital heart defects (CHD) after cardiac surgery."	1.91	Risk Factors and Characteristics of Candidemia After Cardiac Surgery in Pediatric Patients in Central Israel. ( Armoni-Domany, K; Barkai, G; Kahan, Y; Mandelberg, A; Ovadia, A; Shatzman-Steuerman, R; Sherman, G; Shpring, A; Tasher, D; Tope, SG, 2023)
"Candidemia is responsible for substantial morbidity and mortality in neonatal intensive care units and represents a challenge due to the complexity of hospitalized neonates, the deficiency in approved and precise diagnostic techniques, and the increasing number of species resistant to antifungal agents."	1.91	Candidemia in Brazilian neonatal intensive care units: risk factors, epidemiology, and antifungal resistance. ( Amorim, RJM; da Silva, CM; de Carvalho, AMR; Jucá, MB; Macêdo, DPC; Neves, RP, 2023)
"Fluconazole treatment failed, and the patient was successfully treated with liposomal amphotericin B (LAMB)."	1.91	Whole-genome sequencing confirms a persistent candidaemia clonal outbreak due to multidrug-resistant Candida parapsilosis. ( Arastehfar, A; Binder, U; Butler, G; Daneshnia, F; Fuentes, D; Gabaldon, T; Hagen, F; Hilmioğlu-Polat, S; Ilkit, M; Lass-Flörl, C; Lombardi, L; Mansour, MK; Scheler, J, 2023)
"Candidemia is a life-threatening invasive fungal infection in immunocompromised patients."	1.91	Alarming Increase of Azole-Resistant Candida Causing Blood Stream Infections in Oncology Patients in Egypt. ( Abdel-Hamid, RM; Abdelfattah, NE; El-Mahallawy, HA; Wassef, MA, 2023)
"Fluconazole-initiated treatment followed by caspofungin was cost-effective for the treatment of IC/C compared to fluconazole with L-AmB as second-line treatment, at US$316/QALY gained."	1.72	Cost-utility analysis of caspofungin and fluconazole for primary treatment of invasive candidiasis and candidemia in Ethiopia. ( Abebe, W; Alemayehu, T; Ali, EE; Erku, DA; Fentie, AM; Gebremariam, GT; Gebretekle, GB; Sander, B, 2022)
"Candidemia is an alarming problem in critically ill patients including those admitted in intensive care units (ICUs)."	1.62	Candidemia in intensive care units over nine years at a large Italian university hospital: Comparison with other wards. ( Barchiesi, F; Brescini, L; Cerutti, E; Donati, A; Mazzanti, S; Montalti, R; Morroni, G; Munch, C; Orsetti, E; Pocognoli, A, 2021)
"Landscape of candidemia is blurred in Iran, and only two studies from Tehran have extensively explored the epidemiology of candidemia."	1.62	Epidemiology of candidemia in Shiraz, southern Iran: A prospective multicenter study (2016-2018). ( Arastehfar, A; Bakhtiari, M; Boekhout, T; Daneshnia, F; Fang, W; Ilkit, M; Mahmoudi, S; Pakshir, K; Pan, W; Perlin, DS; Yazdanpanah, S; Zand, F; Zomorodian, K, 2021)
"Fluconazole tolerance was strongly associated with death for patients treated with fluconazole within 24 h of candidemia onset (33."	1.62	Impact of tolerance to fluconazole on treatment response in Candida albicans bloodstream infection. ( Ben-Ami, R; Berman, J; Dahan, A; Levinson, T; Novikov, A; Paran, Y, 2021)
" End-of-treatment PTA was highest with the 400 mg twice daily maintenance dosing for patients who were under- or normal weight and 6 mg/kg maintenance dosing for overweight (120 kg) patients."	1.62	Current fluconazole treatment regimens result in under-dosing of critically ill adults during early therapy. ( Day, RO; Marriott, DJE; Norris, RLG; Pang, E; Reuter, SE; Sandaradura, I; Stocker, SL, 2021)
"In fluconazole-treated biofilms, the expression of ERG11 and UPC2 genes was increased."	1.62	The relationship between biofilm formation and mortality in patients with Candida tropicalis candidemia. ( Khodavaisy, S; Rezaie, S; Salehi, M; Sasani, E; Yadegari, MH, 2021)
"Candidemia is the fourth common cause of blood stream infection worldwide leading to increased mortality and morbidity."	1.62	Epidemiology and Antifungal Susceptibility of Candida Species causing Blood Stream Infections: An Eastern India Perspective. ( Banu, H; Chakraborty, M; Gupta, MK, 2021)
"Fluconazole resistance was 13."	1.62	Species distribution, azole resistance and related molecular mechanisms in invasive Candida parapsilosis complex isolates: Increase in fluconazole resistance in 21 years. ( Arikan-Akdagli, S; Demirci-Duarte, S; Gülmez, D, 2021)
"C parapsilosis candidemia is an emerging issue in our center, possibly attributed to some extent to horizontal transmission of the pathogen, as confirmed by the analysis of isolates similarities."	1.56	Changing epidemiology of candidaemia: Increase in fluconazole-resistant Candida parapsilosis. ( Beltramini, S; Codda, G; Del Bono, V; Del Puente, F; Gandolfo, N; Giacobbe, DR; Icardi, G; Marchese, A; Mesini, A; Mikulska, M; Orsi, A; Tassinari, F; Viscoli, C, 2020)
"Voriconazole was the most efficient azole drug."	1.56	Elevated minimum inhibitory concentrations to antifungal drugs prevail in 14 rare species of candidemia-causing Saccharomycotina yeasts. ( Boekhout, T; Lackner, M; Lass-Flörl, C; Pérez-Hansen, A; Stavrou, AA, 2020)
"The mortality of candidemia is affected by the underlying conditions, causative agents and the initial management."	1.51	Mortality and risk factor analysis for Candida blood stream infection: A multicenter study. ( Ide, K; Kato, H; Matsuno, K; Nakajima, H; Shimizu, H; Sugiyama, Y; Suido, Y; Yoshimura, Y, 2019)
"auris colonization/candidemia are similar to other Candida species."	1.51	Detection and treatment of Candida auris in an outbreak situation: risk factors for developing colonization and candidemia by this new species in critically ill patients. ( Alastruey-Izquierdo, A; Calabuig, E; Frasquet, J; López-Hontangas, JL; Martínez, H; Mollar, J; Moret, AM; Pemán, J; Ramírez, P; Ruiz-Gaitán, A; Salavert-Lletí, M; Tasias, M; Zaragoza, Ó, 2019)
"Fluconazole (FLCZ) is an azole antifungal agent and it has shown excellent clinical activities in suppressing fungemia with Candida albicans after hematopoietic stem cell transplantation."	1.48	Breakthrough Candida guilliermondii (Meyerozyma guilliermondii) fungemia after cord blood transplantation for extranodal NK-cell lymphoma with azole prophylaxis. ( Ishida, F; Ito, T; Kikuchi, K; Nakazawa, H; Nishina, S; Sakai, H; Senoo, Y, 2018)
"Antifungals used for treating candidemia were (no IDC/IDC): azoles (74%/42%); echinocandins (0%/46%); liposomal and lipidic complex amphotericin B (0%/12%)."	1.48	Impact of infectious diseases consultation as a part of an antifungal stewardship programme on candidemia outcome in an Italian tertiary-care, University hospital. ( Barnini, S; Bertolino, G; Carmignani, C; Dal Canto, L; Desideri, I; Menichetti, F; Ripoli, A; Rosselli Del Turco, E; Sbrana, F; Sozio, E; Tagliaferri, E; Tascini, C, 2018)
"Although candidemia has been reported globally, little is known about the differences in candidemia episodes between ICU and surgical wards or the correlation between serum biomarkers and mortality from candidemia."	1.48	Clinical characteristics and predictors of mortality in patients with candidemia: a six-year retrospective study. ( Cao, J; Jia, X; Li, C; Wu, X; Zhang, L, 2018)
"Guidelines on treating invasive candidiasis recommend initial treatment with a broad-spectrum echinocandin (e."	1.48	Cost-effectiveness of de-escalation from micafungin versus escalation from fluconazole for invasive candidiasis in China. ( Chen, C; Chen, D; Kruger, E; Wan, X; Wang, L; Wu, J; Yue, X, 2018)
"Candidemia was diagnosed: 5."	1.46	[Epidemiology, species, antifungal resistance and outcome of candidemia in a university hospital in Buenos Aires, Argentina for 16 years]. ( Farías, L; Fernández, NB; García, S; Pozzi, NC; Tiraboschi, IN, 2017)
"The 30-day mortality was 38%; severe sepsis [Odds ratio (OR) 3."	1.46	Impact of inappropriate antifungal therapy according to current susceptibility breakpoints on Candida bloodstream infection mortality, a retrospective analysis. ( Bobadilla-Del-Valle, M; Cornejo-Juárez, P; González-Lara, MF; Martinez-Gamboa, A; Ostrosky-Zeichner, L; Ponce-de-León, A; Rangel-Cordero, A; Sifuentes-Osornio, J; Torres-González, P; Velázquez-Acosta, C, 2017)
"Surveillance of candidemia is essential to monitor trends in species distribution and change in the incidence and antifungal resistance."	1.46	Epidemiology and cost implications of candidemia, a 6-year analysis from a developing country. ( Alp, E; Cevahir, F; Ture, Z; Ulu Kilic, A; Yozgat, N, 2017)
"The clinical context of underlying malignancy and hospitalization in ICU may be relevant to the initial management of candidemia."	1.46	The risk and clinical outcome of candidemia depending on underlying malignancy. ( Bretagne, S; Desnos-Ollivier, M; Dromer, F; Lortholary, O; Renaudat, C; Sitbon, K, 2017)
"The incidence of candidemia is increasing in developing countries."	1.46	A multi-centric Study of Candida bloodstream infection in Lima-Callao, Peru: Species distribution, antifungal resistance and clinical outcomes. ( Agurto, C; Bustamante, B; Diaz, A; Hidalgo, J; Huaroto, L; Illescas, R; Ramirez, R; Rodriguez, L, 2017)
"Whether echinocandins could be used to treat candidemia of a urinary tract source (CUTS) is unknown."	1.46	Echinocandins Compared to Fluconazole for Candidemia of a Urinary Tract Source: A Propensity Score Analysis. ( Aguado, JM; Almirante, B; Ayats, J; Blanco-Vidal, MJ; Cardozo, C; Carratalà, J; Cuervo, G; Fernández-Ruiz, M; Garcia-Vidal, C; González-Barberá, E; Gudiol, C; Manzur, A; Marco, F; Meije, Y; Montejo, JM; Muñoz, P; Pemán, J; Puig-Asensio, M; Vena, A, 2017)
" Noncompartmental pharmacokinetic analysis was performed."	1.43	In Vivo Microdialysis To Determine Subcutaneous Interstitial Fluid Penetration and Pharmacokinetics of Fluconazole in Intensive Care Unit Patients with Sepsis. ( Lassig-Smith, M; Lipman, J; Peake, SL; Roberts, JA; Roberts, MS; Robertson, T; Sinnollareddy, MG; Starr, T, 2016)
"Treatment with fluconazole was successful."	1.43	Community acquired fungemia caused by Candida pulcherrima: diagnostic contribution of MALDI-TOF mass spectrometry. ( Deconinck, L; Melliez, H; Meybeck, A; Patoz, P; Pradier, M; Senneville, E, 2016)
"Candidemia is an increasing problem in tertiary care hospitals worldwide."	1.43	Outbreak of candidemia caused by fluconazole resistant Candida parapsilosis strains in an intensive care unit. ( Casulari, LA; Colombo, AL; Damasceno, CM; Pinhati, HM; Siqueira, RA; Souza, AC, 2016)
"Fluconazole trailing was observed frequently when EUCAST was used for antifungal susceptibility testing, particularly in isolates of C."	1.43	Scope and frequency of fluconazole trailing assessed using EUCAST in invasive Candida spp. isolates. ( Bouza, E; Escribano, P; Guinea, J; Marcos-Zambrano, LJ; Sánchez-Carrillo, C, 2016)
"glabrata, following treatment for candidemia."	1.42	Posttreatment Antifungal Resistance among Colonizing Candida Isolates in Candidemia Patients: Results from a Systematic Multicenter Study. ( Arendrup, MC; Astvad, KM; Dzajic, E; Jensen, RH; Johansen, HK; Kristensen, L; Lemming, LE; Nielsen, L; Olesen, B; Rosenvinge, FS; Søes, LM, 2015)
"Cancer was the most common underlying disease (n = 127, 72."	1.42	Epidemiology and prognostic factors of candidemia in elderly patients. ( Lai, CC; Lin, HL; Liu, WL; Tang, HJ, 2015)
" However, data regarding species-specific dosing targets are inconclusive."	1.42	Differential association of fluconazole dose and dose/MIC ratio with mortality in patients with Candida albicans and non-albicans bloodstream infection. ( Ben-Ami, R; Brosh-Nissimov, T, 2015)
"Anidulafungin was cost-saving versus caspofungin and micafungin due to lower total costs and a higher rate of survival combined with a higher probability of clinical success."	1.42	Cost-effectiveness analysis of anidulafungin for the treatment of candidaemia and other forms of invasive candidiasis. ( Auzinger, G; Charbonneau, C; Graham, CN; Kantecki, M; Knox, HN; Playford, EG; Schlamm, H; Weinstein, D, 2015)
"Malignancy was independently associated with the development of candidemia by non-albicans Candida species (odds ratio 3."	1.40	Predictors and outcomes of Candida bloodstream infection: eight-year surveillance, western Saudi Arabia. ( Al Amri, AF; Al Harbi, MI; Al Thaqafi, AH; Farahat, FM; Perfect, JR, 2014)
"Patients aged 18-99 years with septic shock presenting to Barnes-Jewish Hospital, St."	1.40	Effects of empiric antifungal therapy for septic shock on time to appropriate therapy for Candida infection: a pilot study. ( Arnold, H; Hampton, N; Juang, P; Kollef, M; McKenzie, M; Micek, ST; Scolarici, M, 2014)
"Fluconazole MICs were established using Sensititre(®) YeastOne(®)."	1.40	Support for the EUCAST and revised CLSI fluconazole clinical breakpoints by Sensititre® YeastOne® for Candida albicans: a prospective observational cohort study. ( Chen, SC; Ellis, DH; Marriott, DM; Slavin, M; Sorrell, TC; van Hal, SJ, 2014)
"Amphotericin B was effective for C."	1.40	Antifungal susceptibility of Candida isolates at one institution. ( Horiuchi, C; Ikeda, T; Iwanaga, N; Kamiya, C; Katsuragi, S; Kobayashi, Y; Miyoshi, T; Neki, R; Sata, M; Tanaka, H; Yamanaka, K; Yamashita, Y; Yoshimatsu, J, 2014)
"Micafungin (MCFG) alone was ineffective; however, the combination of MCFG with fosfluconazole (F-FLCZ) successfully treated the patient without a need for any anticoagulant or surgical therapies."	1.39	Successful treatment of recurrent candidemia due to candidal thrombophlebitis associated with a central venous catheter using a combination of fosfluconazole and micafungin. ( Hagiya, H; Kajioka, H, 2013)
" glabrata fluconazole susceptibility breakpoints are predictive of response when fluconazole is dosed appropriately."	1.39	Fluconazole versus an echinocandin for Candida glabrata fungaemia: a retrospective cohort study. ( Carver, PL; Chen, YC; Clancy, CJ; Eschenauer, GA; Klinker, KP; Lam, SW; Lin, SW; Nguyen, MH; Potoski, BA; Shields, RK, 2013)
"Amphotericin B was given to infected infants and prophylactic fluconazole was prescribed to the other noninfected extremely low birth weight infants during the outbreak."	1.39	Reporting an outbreak of Candida pelliculosa fungemia in a neonatal intensive care unit. ( Ho, CM; Ho, MW; Hsieh, HY; Hwang, KP; Lee, CY; Li, TC; Lin, HC; Lin, HY; Lin, MH; Lu, JJ; Su, BH, 2013)
"Fluconazole was the most frequent agent used as primary treatment (65."	1.39	Epidemiology of candidemia in Latin America: a laboratory-based survey. ( Alvarado-Matute, T; Colombo, AL; Cortes, J; Echevarria, JI; Guzman-Blanco, M; Nucci, M; Queiroz-Telles, F; Santolaya, ME; Sifuentes-Osornio, J; Thompson, L; Tiraboschi, IN; Zurita, J, 2013)
"Most subjects (62%) had hematologic malignancies."	1.39	Risk factors and outcomes of Candida krusei bloodstream infection: a matched, case-control study. ( Lloyd, L; Meibohm, A; Schuster, MG; Strom, B, 2013)
"Once candidemia is found, ophthalmologic examination and systemic antifungal therapy are needed."	1.38	[A study for candidemia during the six year period from 1993 to 1999 in St. Luke's International Hospital]. ( Furukawa, K; Kazama, I, 2012)
"Invasive candidiasis is rare in children after the neonatal period, but can occur in children with (secondary) immunodeficiency with a damaged gastrointestinal or skin barrier, or when receiving antibiotics."	1.37	Osteoarticular infection by Candida albicans in an infant with cystic fibrosis. ( Abele-Horn, M; Beer, M; Hebestreit, H; Kunzmann, S; Radike, K, 2011)
"Fluconazole was the most common agent prescribed for the treatment of candidaemia."	1.37	Epidemiology and management of candidaemia--a retrospective, multicentre study in five hospitals in the UK. ( Bal, AM; Chalmers, C; Chew, J; Gaur, S; Gould, IM; Kumar, A; Leanord, A; Mathur, S; Wan, WY; Wright, T, 2011)
"Fluconazole resistance was observed among 26% of all Candida isolates and 17."	1.37	An observational study on the epidemiological and mycological profile of Candidemia in ICU patients. ( Biswas, D; Gupta, A; Jindal, P; Kotwal, A; Sharma, JP, 2011)
"Voriconazole resistance was absent."	1.37	Bloodstream yeast infections in a university hospital in Northeast Turkey: a 4-year survey. ( Aydin, F; Bayramoglu, G; Guler, NC; Kaklikkaya, N; Tosun, I, 2011)
"Anidulafungin as first-line treatment of C/IC appears to be of particular benefit to ICU patients, improving clinical outcomes and possibly decreasing costs, driven by reduced ICU and hospital stay, when compared with fluconazole."	1.37	Resource utilization and cost of treatment with anidulafungin or fluconazole for candidaemia and other forms of invasive candidiasis: focus on critically ill patients. ( Cartier, S; Chambers, R; Kett, DH; Maschio, M; Reboli, AC; Rotstein, C; Tarallo, M, 2011)
"Anidulafungin was effective in the treatment of patients with documented candidemia arising from different sites, and no significant side effects were observed."	1.36	Clinical experience of anidulafungin for the treatment of patients with documented candidemia. ( De Rosa, FG; Falcone, M; Ghezzi, MC; Pasero, D; Raponi, G; Russo, A; Toma, L; Venditti, M, 2010)

Research

Studies (227)

Authors

Clinical Trials (10)

Trial Overview

Trial Outcomes

Day 90 Survival

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	162 (71.37)	24.3611
2020's	65 (28.63)	2.80

Authors	Studies
Hamad, A	1
Chen, Y	1
Khan, MA	1
Jamshidi, S	1
Saeed, N	1
Clifford, M	1
Hind, C	1
Sutton, JM	1
Rahman, KM	1
Chakraborty, M	1
Banu, H	1
Gupta, MK	1
Yılmaz-Ciftdoğan, D	1
Kara-Aksay, A	1
Erbaş, G	1
Sarkış, ÜB	1
Karadağ-Oncel, E	1
Anıl, AB	1
Baran, M	1
Er, H	1
Yılmaz, N	1
Mesquida, A	1
Díaz-García, J	1
Sánchez-Carrillo, C	2
Muñoz, P	3
Escribano, P	2
Guinea, J	6
Bavaro, DF	1
Balena, F	1
Ronga, L	1
Signorile, F	1
Romanelli, F	1
Stolfa, S	1
Sparapano, E	1
De Carlo, C	1
Mosca, A	1
Monno, L	1
Angarano, G	1
Saracino, A	1
Vannini, M	1
Emery, S	1
Lieutier-Colas, F	1
Legueult, K	1
Mondain, V	1
Retur, N	1
Gastaud, L	1
Pomares, C	1
Hasseine, L	1
Memon, S	1
Farooqi, J	1
Zafar, U	1
Naqvi, SF	1
Zafar, A	1
Jabeen, K	1
Yuan, G	1
Tu, Y	1
Liu, L	1
Xu, T	1
Broderick, KL	1
Peters, CJ	1
Mazurek, JA	1
Wald, J	1
Zhang, RS	1
Atluri, P	1
Urgo, K	1
Goldberg, L	1
Blumberg, EA	1
Weikert, BC	1
Birati, EY	1
Mirza, A	1
Senol, E	1
Kalkanci, A	2
Atiencia-Carrera, MB	1
Cabezas-Mera, FS	1
Tejera, E	1
Machado, A	1
Lim, YK	1
Kweon, OJ	1
Kim, HR	2
Kim, TH	1
Lee, MK	3
Kajihara, T	1
Yahara, K	1
Nagi, M	1
Kitamura, N	1
Hirabayashi, A	1
Hosaka, Y	1
Abe, M	1
Miyazaki, Y	1
Sugai, M	1
Tsukamoto, H	1
Higashi, T	1
Kodawara, T	1
Watanabe, K	1
Hida, Y	1
Iwasaki, H	1
Goto, N	1
Gebretekle, GB	1
Fentie, AM	1
Gebremariam, GT	1
Ali, EE	1
Erku, DA	1
Alemayehu, T	1
Abebe, W	1
Sander, B	1
Kraft, L	1
Ribeiro, VST	1
Gonçalves, GA	1
Suss, PH	1
Tuon, FF	1
Bourassa-Blanchette, S	1
Biesheuvel, MM	1
Lam, JC	1
Kipp, A	1
Church, D	1
Carson, J	1
Dalton, B	1
Parkins, MD	1
Barkema, HW	1
Gregson, DB	1
Kahan, Y	1
Tope, SG	1
Ovadia, A	1
Shpring, A	1
Shatzman-Steuerman, R	1
Sherman, G	1
Barkai, G	1
Mandelberg, A	1
Armoni-Domany, K	1
Tasher, D	1
da Silva, CM	1
de Carvalho, AMR	1
Macêdo, DPC	1
Jucá, MB	1
Amorim, RJM	1
Neves, RP	1
Daneshnia, F	5
Hilmioğlu-Polat, S	2
Ilkit, M	5
Fuentes, D	1
Lombardi, L	2
Binder, U	1
Scheler, J	1
Hagen, F	4
Mansour, MK	1
Butler, G	1
Lass-Flörl, C	4
Gabaldon, T	2
Arastehfar, A	5
de Almeida Júnior, JN	1
Perry, AM	1
Gao, M	1
Nobile, CJ	1
Egger, M	1
Perlin, DS	3
Zhai, B	1
Hohl, TM	1
Colombo, AL	5
Hoenigl, M	2
Sharifi, M	1
Badiee, P	1
Abastabar, M	1
Morovati, H	1
Haghani, I	1
Noorbakhsh, M	1
Mohammadi, R	1
Carbia, M	1
Medina, V	1
Bustillo, C	1
Martínez, C	1
González, MP	1
Ballesté, R	1
Naicker, SD	3
Shuping, L	1
Zulu, TG	1
Mpembe, RS	2
Mhlanga, M	1
Tsotetsi, EM	1
Maphanga, TG	2
Govender, NP	4
El-Mahallawy, HA	1
Abdelfattah, NE	1
Wassef, MA	1
Abdel-Hamid, RM	1
Fernández-Ruiz, M	6
Cardozo, C	2
Salavert, M	2
Aguilar-Guisado, M	1
Escolà-Vergé, L	1
Gioia, F	1
Montejo, M	1
Merino, P	2
Cuervo, G	3
García-Vidal, C	3
Aguado, JM	6
Ahmad, S	3
Khan, Z	3
Al-Sweih, N	2
Alfouzan, W	2
Joseph, L	2
Aldardeer, NF	1
Albar, H	1
Al-Attas, M	1
Eldali, A	1
Qutub, M	1
Hassanien, A	1
Alraddadi, B	1
Mesini, A	1
Mikulska, M	2
Giacobbe, DR	1
Del Puente, F	1
Gandolfo, N	1
Codda, G	1
Orsi, A	1
Tassinari, F	1
Beltramini, S	1
Marchese, A	1
Icardi, G	1
Del Bono, V	2
Viscoli, C	3
Martín-Gutiérrez, G	1
Peñalva, G	1
Ruiz-Pérez de Pipaón, M	1
Aguilar, M	1
Gil-Navarro, MV	1
Pérez-Blanco, JL	1
Pérez-Moreno, MA	1
Amaya-Villar, R	1
Ferrándiz-Millón, C	1
Gascón, ML	1
Goycochea-Valdivia, WA	1
Jiménez-Mejías, ME	1
Navarro, MD	1
Lepe, JA	1
Alvarez-Marín, R	1
Neth, O	1
Guisado-Gil, AB	1
Infante-Domínguez, C	1
Molina, J	1
Cisneros, JM	1
Bienvenu, AL	1
Pradat, P	1
Guerin, C	1
Aubrun, F	1
Fellahi, JL	1
Friggeri, A	1
Guichon, C	1
Hernu, R	1
Menotti, J	1
Monard, C	1
Paulus, S	1
Rimmele, T	1
Piriou, V	1
Chidiac, C	1
Argaud, L	1
Leboucher, G	1
Ahangarkani, F	1
Shokohi, T	1
Rezai, MS	1
Mahmoodi Nesheli, H	1
Karami, H	1
Tamaddoni, A	1
Alizadeh-Navaei, R	1
Khodavaisy, S	4
Meis, JF	3
Badali, H	1
Stavrou, AA	1
Pérez-Hansen, A	1
Lackner, M	1
Boekhout, T	3
Shastri, PS	1
Shankarnarayan, SA	1
Oberoi, J	1
Rudramurthy, SM	2
Wattal, C	2
Chakrabarti, A	3
Magobo, RE	2
Lockhart, SR	7
Jung, IY	1
Jeong, SJ	1
Kim, YK	1
Kim, HY	1
Song, YG	1
Kim, JM	1
Choi, JY	1
Al-Baqsami, ZF	1
Doğan, Ö	1
Yeşilkaya, A	1
Menekşe, Ş	1
Güler, Ö	1
Karakoç, Ç	1
Çınar, G	1
Kapmaz, M	1
Aydın, M	1
Keske, Ş	1
Şahin, S	1
Hacıseyitoğlu, D	1
Yalçın, D	1
Tekin, S	1
Ataç, N	1
Albayrak, Ö	1
Aksu, ED	1
Can, F	1
Ergönül, Ö	1
Salehi, M	3
Yaşar, M	1
Hoşbul, T	1
Pan, W	3
Arslan, N	1
Türk-Dağı, H	1
Dalla Lana, DF	1
Falci, DR	1
Sanha, V	1
Jaskulski Filho, SD	1
Schuch, F	1
Pasqualotto, AC	1
Song, KY	1
Park, C	1
Byun, JH	1
Chun, HS	1
Choi, JH	1
Han, EH	1
Lee, SO	1
Jeong, Y	1
Kim, YJ	1
Kim, SH	2
Xie, O	1
Streitberg, R	1
Hughes, C	1
Stuart, R	1
Graham, M	1
Yoo, JR	1
Shin, BR	1
Jo, S	1
Heo, ST	1
Zhang, W	1
Song, X	1
Wu, H	1
Zheng, R	1
Yazdanpanah, S	1
Bakhtiari, M	1
Fang, W	1
Mahmoudi, S	1
Pakshir, K	1
Zomorodian, K	2
Zand, F	1
Ateş, U	1
Gurbanova, A	1
Yiğitoğlu, FN	1
Raja, NS	1
Lee, CH	2
Chen, YC	5
Chen, IL	1
Chen, FJ	2
Chien, CC	1
Levinson, T	1
Dahan, A	1
Novikov, A	1
Paran, Y	1
Berman, J	2
Ben-Ami, R	5
Bal, AM	4
Chen, SM	1
Zou, Z	1
Guo, SY	1
Hou, WT	1
Qiu, XR	1
Zhang, Y	1
Song, LJ	1
Hu, XY	1
Jiang, YY	2
Shen, H	1
An, MM	1
Sunny, S	1
Episcopia, B	1
Boudourakis, L	1
Xavier, G	1
Quale, J	1
Won, EJ	1
Choi, MJ	1
Kim, MN	1
Yong, D	1
Lee, WG	1
Uh, Y	1
Kim, TS	1
Byeon, SA	1
Lee, SY	2
Shin, JH	1
Sandaradura, I	1
Marriott, DJE	1
Day, RO	1
Norris, RLG	1
Pang, E	1
Stocker, SL	1
Reuter, SE	1
Sasani, E	2
Rezaie, S	2
Yadegari, MH	2
De Rosa, FG	3
Busca, A	1
Capparella, MR	2
Yan, JL	2
Aram, JA	1
Demirci-Duarte, S	1
Arikan-Akdagli, S	1
Gülmez, D	1
Mazzanti, S	1
Brescini, L	1
Morroni, G	1
Orsetti, E	1
Pocognoli, A	1
Donati, A	1
Cerutti, E	1
Munch, C	1
Montalti, R	1
Barchiesi, F	1
Gold, JAW	1
Seagle, EE	1
Nadle, J	1
Barter, DM	1
Czaja, CA	1
Johnston, H	1
Farley, MM	3
Thomas, S	1
Harrison, LH	3
Fischer, J	1
Pattee, B	1
Mody, RK	1
Phipps, EC	1
Davis, SS	1
Tesini, BL	1
Zhang, AY	2
Markus, TM	1
Schaffner, W	3
Vallabhaneni, S	2
Jackson, BR	1
Lyman, M	1
Soulountsi, V	1
Schizodimos, T	1
Kotoulas, SC	1
Kato, H	2
Hagihara, M	1
Shibata, Y	1
Asai, N	1
Yamagishi, Y	1
Iwamoto, T	1
Mikamo, H	1
Kwenda, S	1
Muñoz, JF	1
van Schalkwyk, E	1
Wadula, J	2
Nana, T	2
Ismail, A	1
Coetzee, J	1
Govind, C	1
Mtshali, PS	1
Getso, MI	1
Lortholary, O	2
Renaudat, C	1
Sitbon, K	2
Desnos-Ollivier, M	2
Bretagne, S	2
Dromer, F	2
Puig-Asensio, M	6
Vena, A	1
Meije, Y	1
González-Barberá, E	1
Blanco-Vidal, MJ	1
Manzur, A	1
Gudiol, C	2
Montejo, JM	1
Pemán, J	4
Ayats, J	2
Marco, F	1
Almirante, B	7
Carratalà, J	2
Paul, RA	1
Sood, P	1
Kaur, H	1
Capoor, MR	1
Kindo, AJ	1
Marak, RSK	1
Arora, A	1
Sardana, R	1
Das, S	1
Chhina, D	1
Patel, A	1
Xess, I	1
Tarai, B	1
Singh, P	1
Ghosh, A	1
Chapman, B	1
Slavin, M	2
Marriott, D	1
Halliday, C	1
Kidd, S	1
Arthur, I	1
Bak, N	1
Heath, CH	1
Kennedy, K	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Evaluation of a Clinical Decision Support System for the Treatment of Invasive Fungal Infections[NCT05656157]		100 participants (Anticipated)	Observational	2022-12-01	Active, not recruiting
Open-Label, Non-Comparative, Study Of Intravenous Anidulafungin, Followed Optionally By Oral Voriconazole Or Fluconazole Therapy, For Treatment Of Documented Candidemia/Invasive Candidiasis In Intensive Care Unit Patient Populations[NCT00689338]	Phase 3	216 participants (Actual)	Interventional	2008-07-31	Completed
Efficacy And Safety Of Eraxis/Ecalta (Anidulafungin) Compared To Cancidas (Caspofungin) In Patients With Candida Deep Tissue Infection[NCT00805740]	Phase 3	41 participants (Actual)	Interventional	2009-04-30	Terminated (stopped due to The study was terminated prematurely on May 18, 2012 due to slow enrollment. The study was not terminated due to any safety issues or concerns.)
Efficacy And Safety Of Eraxis/Ecalta (Anidulafungin) Compared To Cancidas (Caspofungin) In Neutropenic Patients With Invasive Candida Infection[NCT00806351]	Phase 3	21 participants (Actual)	Interventional	2009-08-31	Terminated (stopped due to The study was prematurely terminated on May 18, 2012 due to slow enrollment. The study was not terminate due to any safety issues or concerns.)
Open-Label, Non-Comparative, Study Of Intravenous Anidulafungin, Followed Optionally By Oral Voriconazole, For Treatment Of Documented Candidemia/Invasive Candidiasis In Hospitalized Patients[NCT00548262]	Phase 4	54 participants (Actual)	Interventional	2008-02-29	Completed
Phase IV Open Label Non Comparative Trial Of IV Anidulafungin Followed By Oral Azole Therapy For The Treatment Of Candidemia And Invasive Candidiasis[NCT00496197]	Phase 4	282 participants (Actual)	Interventional	2007-07-31	Completed
A Phase IIIB Pilot Study Of Efficacy And Safety Of Anidulafungin In The Treatment Of Candidemia In Asian Patients[NCT00537329]	Phase 3	43 participants (Actual)	Interventional	2008-01-31	Completed
Prospective Population Study on Candidemia in Spain (Estudio Poblacional Prospectivo Sobre Candidemia en España)[NCT01236261]		730 participants (Actual)	Observational	2013-03-31	Completed
A Phase III, Double Blind, Randomized, Multi-Center Study of the Safety and Efficacy of Anidulafungin VS. Fluconazole in the Treatment of Patients With Candidemia and Other Forms of Invasive Candidiasis and Prevention of Complications[NCT00058682]	Phase 3	248 participants	Interventional	2003-04-30	Completed
Efflux Pump Mediated Azole Resistance in Candida Albicans Among Neutropenic Patients With Haematological Malignancies[NCT03659162]		100 participants (Anticipated)	Observational	2019-02-17	Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Percentage of participants known or assumed to be alive on Day 90. (NCT00689338)
Timeframe: Day 90

Percentage of Participants With Global Response Success 6 Weeks After End of Treatment

Intervention	percentage of participants (Number)
Anidulafungin	54.1

Global response based on combination of clinical and microbiological outcomes; success defined as clinical response of cure (resolution of signs and symptoms of Candida infection) or improvement (significant, but incomplete resolution of signs and symptoms of Candida infection) in conjunction with microbiological eradication (follow-up culture negative for Candida species) or presumed eradication (follow-up culture not available and clinical response of success). (NCT00689338)
Timeframe: 6 weeks after End of Treatment (Day 14 + 42 up to Day 56 + 42)

Percentage of Participants With Global Response Success at 2 Weeks After End of Treatment

Intervention	percentage of participants (Number)
Anidulafungin	50.5

Global response based on combination of clinical and microbiological outcomes; success defined as clinical response of cure (resolution of signs and symptoms of Candida infection) or improvement (significant, but incomplete resolution of signs and symptoms of Candida infection) in conjunction with microbiological eradication (follow-up culture negative for Candida species) or presumed eradication (follow-up culture not available and clinical response of success). (NCT00689338)
Timeframe: 2 weeks after End of Treatment (Day 14 + 14 up to Day 56 + 14)

Percentage of Participants With Global Response Success at End of Intravenous Treatment (EOIVT)

Intervention	percentage of participants (Number)
Anidulafungin	60.2

Percentage of Participants With Global Treatment Response Success at End of Treatment

Intervention	percentage of participants (Number)
Anidulafungin	70.7

Time to First Negative Blood Culture

Intervention	percentage of participants (Number)
Anidulafungin	69.5

Negative blood culture defined as first negative culture that was not followed by a positive culture within the next 3 days (or 4 days if negative culture was observed on or after Day 10) from start of study medication until end of intravenous treatment (EOIVT). Time to first negative culture includes the first day of study medication. (NCT00689338)
Timeframe: Day 1 up to Day 42

Time to Successful Intensive Care Unit (ICU) Discharge

Intervention	days (Mean)
Anidulafungin	3.7

Time from start of study medication to successful ICU discharge (by end of treatment [EOT]), defined as being alive on the day after the EOT visit, not being in the ICU on the day after the EOT visit, and being classed as a global treatment success at EOT. (NCT00689338)
Timeframe: Day 1 up to Day 56

Percentage of Participants With Clinical Response

Intervention	days (Mean)
Anidulafungin	16.2

A participant had a successful clinical response if there was clinical response of cure or improvement. Clinical response of cure: resolution of signs and symptoms attributed to Candida infection; no additional systemic or oral antifungal treatment required to complete the course of therapy. Clinical response of improvement: significant, but incomplete resolution of signs and symptoms of Candida infection; no additional systemic or oral antifungal treatment required. (NCT00805740)
Timeframe: Day 10

Percentage of Participants With Global Response at End of Treatment (Day 14 To Day 42)

Intervention	percentage of participants (Number)
Anidulafungin	70.8
Caspofungin	76.9

Participants had successful global response if there was clinical response of cure/improvement,microbiological eradication/presumed eradication.Clinical cure:resolution of signs/symptoms (s/s) of Candida infection;no additional systemic/oral antifungal treatment needed.Clinical improvement:significant,but incomplete resolution of s/s of Candida infection;no additional systemic/oral antifungal treatment needed.Microbiological eradication/presumed eradication:baseline pathogen not isolated from original site culture,or culture data not available for participant with successful clinical outcome. (NCT00805740)
Timeframe: End of Treatment (Day 14 to Day 42)

Time to Death

Intervention	percentage of participants (Number)
Anidulafungin	83.3
Caspofungin	61.5

Time to death (days) was assessed as date of death minus first treatment date plus 1. (NCT00805740)
Timeframe: Baseline up to 6-week follow-up (6 weeks after EOT)

Time to Negative Blood Culture

Intervention	days (Median)
Anidulafungin	23.0
Caspofungin	11.5

Negative blood culture referred to absence of Candida sp. in the blood sample of participants who had a positive blood culture at baseline. Time to negative blood culture (days) was calculated as date of first negative blood culture minus first treatment date plus 1. (NCT00805740)
Timeframe: Baseline up to 6-week follow-up (6 weeks after EOT)

Percentage of Participants With All-cause Mortality

Intervention	days (Median)
Anidulafungin	2.0
Caspofungin	3.5

All-cause mortality during study therapy and at follow-up visits reported as unique death at EOT, 2 week follow-up and 6 week follow-up. (NCT00805740)
Timeframe: Baseline to EOT (Day 14 to 42), After EOT to 2-week follow-up (2 weeks after EOT), After 2-week follow-up to 6-week follow-up (6 weeks after EOT)

Percentage of Participants With Global Response at 2-week and 6-week Follow-up Visit

Intervention	percentage of participants (Number)
	Baseline to EOT	After EOT to 2-week follow-up	After 2-week follow-up to 6-week follow-up
Anidulafungin	3.8	15.4	7.7
Caspofungin	15.4	15.4	0.0

Percentage of Participants With New Infection

Intervention	percentage of participants (Number)
	2-week follow-up	6-week follow-up
Anidulafungin	76.2	66.7
Caspofungin	54.5	54.5

New Infection: participant presenting with clinical failure with the emergence of new Candida sp. at the original site of infection or at a distant site of infection. Clinical failure: no significant improvement in signs and symptoms, or death due to Candida infection. Participants must have had received at least 3 doses of study drug to be classified as a failure. (NCT00805740)
Timeframe: 2-week follow-up (2 weeks after EOT), 6-week follow-up (6 weeks after EOT)

Percentage of Participants With Relapse

Intervention	percentage of participants (Number)
	2-week follow-up	6-week follow-up
Anidulafungin	0	0
Caspofungin	0	0

Relapse was defined as any baseline Candida sp. isolated following eradication (documented or presumed) or culture data not available for participants with a clinical response of failure after a previous response of success. Prophylactic treatment with oral antifungal agents was not sufficient to document a relapse. (NCT00805740)
Timeframe: 2-week follow-up (2 weeks after EOT), 6-week follow-up (6 weeks after EOT)

Percentage of Participants With Response Based on Clinical Cure and Microbiological Success

Intervention	percentage of participants (Number)
	2-week follow-up	6-week follow-up
Anidulafungin	0	0
Caspofungin	0	0

A participant had a successful response if there was clinical response of cure and microbiological success (eradication or presumed eradication). Clinical response of cure: resolution of signs and symptoms attributed to Candida infection; no additional systemic or oral antifungal treatment required to complete the course of therapy. Microbiological eradication or presumed eradication: baseline pathogen not isolated from original site culture, or culture data not available for a participant with successful clinical outcome. (NCT00805740)
Timeframe: EOT (Day 14 to 42), 2-week follow-up (2 weeks after EOT), 6-week follow-up (6 weeks after EOT)

Response Based on Clinical Cure and Microbiological Success at 2-Week Follow-Up Visit

Intervention	percentage of participants (Number)
	EOT (n=21,8)	2-week follow-up (n=16,6)	6-week follow-up (n=15,6)
Anidulafungin	81.0	87.5	93.3
Caspofungin	62.5	100.0	100.0

Participant counts of clinical cure (no s/s of Candida) and microbiological success (eradication [f/u culture negative] or presumed eradication [f/u culture not available and a clinical response of cure]). (NCT00806351)
Timeframe: 2 weeks post treatment

Response Based on Clinical Cure and Microbiological Success at 6-Week Follow-Up Visit

Intervention	participants (Number)
Anidulafungin	4
Caspofungin	1

Response Based on Clinical Cure and Microbiological Success at EOIVT

Intervention	participants (Number)
Anidulafungin	6
Caspofungin	1

Response Based on Clinical Cure and Microbiological Success at EOT

Intervention	participants (Number)
Anidulafungin	7
Caspofungin	2

Time to Death

Intervention	participants (Number)
Anidulafungin	6
Caspofungin	3

Time to death defined as: date of death minus first treatment date plus 1. (NCT00806351)
Timeframe: Day 1 up to Day 98

Time to First Negative Blood Culture for Candida Species

Intervention	days (Median)
Anidulafungin	34.0
Caspofungin	15.5

A participant had a negative blood culture, if having determined the day of the first negative blood culture, the subsequent blood culture was also negative, or if positive, the interval between the cultures was at least 2 days. For participants whose blood culture went from positive to negative, the time to negative blood culture defined as: date of first negative blood culture minus first treatment date plus 1. (NCT00806351)
Timeframe: Baseline up to Day 56

All-Cause Mortality

Intervention	days (Median)
Anidulafungin	2.0

All-cause mortality during study therapy and at follow-up visits reported as unique deaths at EOIVT, end of oral treatment (EOT-oral), 2 Week Follow-Up and 6 Week Follow-Up (NCT00806351)
Timeframe: Baseline up to 6 weeks post treatment

Clinical Response at Day 10

Intervention	participants (Number)
	at EOIVT	at EOT - oral	at 2 Week Follow-Up Visit	at 6 Week Follow-Up Visit
Anidulafungin	1	1	1	2
Caspofungin	1	0	3	0

Participant counts of clinical response categorized as success, failure, or indeterminate. Success: no s/s of Candida (cure) or significant but incomplete resolution of s/s of Candida; no additional systemic or oral antifungal treatment required (improvement). Failure: worsening of s/s of the Candida infection. Indeterminate: evaluation could not be made due to withdrawal from study prior to assessment of cure or failure. Participants who received fewer than 3 doses of study medication were assigned a clinical efficacy response of indeterminate. (NCT00806351)
Timeframe: Day 10

Global Response at 2-Week Follow-Up Visit

Intervention	participants (Number)
	Success	Failure	Indeterminate
Anidulafungin	7	0	2
Caspofungin	3	0	0

Participant counts of global response of success, failure, or indeterminate. Success: clinical response of cure (no s/s of Candida) or improvement (significant, incomplete resolution of s/s) and microbiological response of eradication (f/u culture negative) or presumed eradication (f/u culture not available and clinical success). Failure: clinical response of failure (≥3 doses study medication and no significant improvement of s/s or death due to Candida) and/or unsuccessful microbiological response of persistent (positive culture any Candida sp), new infection or relapse at f/u. Indeterminate: clinical and/or microbiological response of indeterminate (evaluation could not be made due to withdrawal from study prior to assessment of cure or failure) and there was neither clinical response of failure nor unsuccessful microbiological response (persistence or new infection or relapse). (NCT00806351)
Timeframe: 2 weeks post treatment

Global Response at 6-Week Follow-Up Visit

Intervention	participants (Number)
	Success	Failure	Indeterminate
Anidulafungin	6	3	0
Caspofungin	1	0	0

Global Response at End of Intravenous Treatment (EOIVT)

Intervention	participants (Number)
	Success	Failure	Indeterminate
Anidulafungin	5	4	0
Caspofungin	1	0	0

Participant counts of global response of success, failure, or indeterminate. Success: clinical response of cure (no signs, symptoms [s/s] of Candida) or improvement (significant, incomplete resolution of s/s) and microbiological response of eradication (follow-up [f/u] culture negative) or presumed eradication (f/u culture not available and clinical success). Failure: clinical response of failure (greater than or equal to [≥3] doses study medication and no significant improvement of s/s or death due to Candida) and/or unsuccessful microbiological response of persistent(positive culture any Candida species [sp]), new infection or relapse at f/u. Indeterminate: clinical and/or microbiological response of indeterminate (evaluation could not be made due to withdrawal from study prior to assessment of cure or failure) and there was neither clinical response of failure nor unsuccessful microbiological response (persistence or new infection or relapse). (NCT00806351)
Timeframe: Day 10 up to Day 42

Global Response at End of Treatment (EOT)

Intervention	participants (Number)
	Success	Failure	Indeterminate
Anidulafungin	8	3	0
Caspofungin	3	0	0

Number of Participants With New Infections

Intervention	participants (Number)
	Success	Failure	Indeterminate
Anidulafungin	8	3	0
Caspofungin	3	0	0

Participant counts of microbiologic response of new infection defined as clinical failure with emergence of new Candida sp not identified at baseline at the original site of infection or at a distant site of infection. Clinical failure defined as ≥3 doses study medication and no significant improvement of s/s or death due to Candida. (NCT00806351)
Timeframe: 2 and 6 weeks post treatment

Number of Participants With Recurrence

Intervention	participants (Number)
	2 weeks post treatment	6 weeks post treatment
Anidulafungin	0	0
Caspofungin	0	0

Participant counts of microbiologic response of recurrence defined as any baseline Candida sp isolated following eradication, or culture data were not available for participants with a clinical response of failure after a previous response of success. Clinical failure defined as ≥3 doses study medication and no significant improvement of s/s or death due to Candida. Clinical success is resolution of s/s and no additional antifungal treatment needed. (NCT00806351)
Timeframe: 2 and 6 weeks post treatment

Duration of Exposure to Intravenous Anidulafungin Prior to Switch to Oral Voriconazole Treatment

Intervention	participants (Number)
	2 Weeks post treatment	6 Weeks post treatment
Anidulafungin	0	0
Caspofungin	0	0

Defined as time in days from first intravenous administration of Anidulafungin to the date of earliest recorded documentation of switch to oral Voriconazole treatment. Participants received at least 5 days (and a maximum of 42 days) of IV Anidulafungin; after this, they may continue treatment with oral Voriconazole for at least 14 days from the day of last positive culture up to a maximum of 42 days. (NCT00548262)
Timeframe: Baseline to Day 42

Length of Stay in Intensive Care Unit (ICU)

Intervention	days (Median)
Anidulafungin-Voriconazole	10.0

Defined as the number of days from date of first drug administration to date of first ICU discharge. Week 6 Follow-up visit conducted by phone. (NCT00548262)
Timeframe: Baseline up to Week 6 Follow-up

Change From Baseline in Chemistry Laboratory Test Data (Measured as IU/L)

Intervention	Days (Median)
Anidulafungin-Voriconazole	16.0

Chemistry laboratory test data measured as international units per (IU/L). (NCT00548262)
Timeframe: Baseline to Week 2 Follow-up

Change From Baseline in Chemistry Laboratory Test Data (Measured as mg/dL)

Intervention	IU/L (Median)
	Baseline median: aspartate aminotransferase (n=18)	Change from baseline: aspartate aminotransferase	Baseline median: alanine aminotransferase (n=16)	Change from baseline: alanine aminotransferase	Baseline median: lactate dehydrogenase (n=13)	Change from baseline: lactate dehydrogenase	Baseline median: alkaline phosphatase (n=17)	Change from baseline: alkaline phosphatase
Anidulafungin-Voriconazole	43	-18	45	-5	536	-160	114	26

Chemistry laboratory test data measured as milligrams per deciliter (mg/dL). (NCT00548262)
Timeframe: Baseline to Week 2 Follow-up

Change From Baseline in Vital Signs: Respiration Rate

Intervention	mg/dL (Median)
	Baseline median: total bilirubin (n=19)	Change from baseline: total bilirubin	Baseline median: direct bilirubin (n=19)	Change from baseline: direct bilirubin	Baseline median: indirect bilirubin (n=17)	Change from baseline: indirect bilirubin	Baseline median: blood urea nitrogen (n=25)	Change from baseline: blood urea nitrogen	Baseline median: creatinine (n=27)	Change from baseline: creatinine	Baseline median: glucose (n=24)	Change from baseline: glucose
Anidulafungin-Voriconazole	0.6	-0.2	0.2	-0.1	0.3	0.0	37.4	-4.8	0.8	0.0	99	-6

Respiration rate measured as respirations per minute (resp/min). (NCT00548262)
Timeframe: Baseline to Week 2 Follow-up

Change From Baseline in Vital Signs: Supine Blood Pressure

Intervention	resp/min (Median)
	Baseline median: respiration rate	Change from baseline: respiration rate
Anidulafungin-Voriconazole	20.0	-0.50

Supine systolic and diastolic blood pressure BP) measured as millimeters of mercury (mmHg). (NCT00548262)
Timeframe: Baseline to Week 2 Follow-up

Change From Baseline in Vital Signs: Supine Heart Rate

Intervention	mmHg (Median)
	Baseline median: supine systolic BP	Change from baseline: supine systolic BP	Baseline median: supine diastolic BP	Change from baseline: supine diastolic BP
Anidulafungin-Voriconazole	120.0	0.00	66.0	0.00

Supine heart rate measured as beats per minute (bpm). (NCT00548262)
Timeframe: Baseline to Week 2 Follow-up

Change From Baseline in Vital Signs: Temperature

Intervention	bpm (Median)
	Baseline median: supine heart rate	Change from baseline: supine heart rate
Anidulafungin-Voriconazole	97.5	3.00

Temperature measured as degrees of Celsius (C). (NCT00548262)
Timeframe: Baseline to Week 2 Follow-up

Change From Baseline in Vital Signs: Weight

Intervention	Degrees of Celsius (Median)
	Baseline median: temperature	Change from baseline: temperature
Anidulafungin-Voriconazole	37.5	-0.30

Weight measured as kilograms (kg). (NCT00548262)
Timeframe: Baseline to Week 2 Follow-up

Number of Participants for Global Response (Based on Clinical and Microbiological Success or Failure)

Intervention	kg (Median)
	Baseline median: weight	Change from baseline: weight
Anidulafungin-Voriconazole	65.0	-0.70

Clinical Success (cure=resolution of Candida signs and symptoms [s/s] or improvement=significant but incomplete resolution of s/s) or Failure (at least 3 doses Anidulafungin with no significant improvement in s/s or death due to Candida) and Microbiological Success (eradication=negative culture for baseline Candida species (spp) or presumed eradication=follow-up (f/u) culture not available (n/a) and clinical outcome defined as success) or Failure (persistence=positive culture for at least 1 baseline Candida spp or presumed persistence=f/u culture n/a and clinical outcome defined as failure). (NCT00548262)
Timeframe: End of Intravenous Treatment (EIVT) (up to Day 42), Week 2 Follow-up

Number of Participants for Global Response (Based on Clinical and Microbiological Success or Failure) at End of Treatment

Intervention	participants (Number)
	EIVT Success	EIVT Failure	Week 2 Follow-up Success	Week 2 Follow-up Failure
Anidulafungin-Voriconazole	26	18	21	23

Number of Participants for Global Response by Acute Physiological Assessment and Chronic Health Evaluation II (APACHE II) Score

Intervention	participants (Number)
	Success	Failure
Anidulafungin-Voriconazole	26	18

Global response based on assessments of Clinical Success or Failure and Microbiological Success or Failure. Categorized as global Success if both clinical and microbiological response=success; Failure defined as all other combinations. Global response assessed as APACHE II score <20 (less affected) or ≥20 (more severe). APACHE II assesses severity of illness in acutely ill participants; measurements computed for physiologic variables were transformed to integer score ranging 0 (normal) to 71 (more severe). Higher scores indicate more severe disease and higher risk of death. (NCT00548262)
Timeframe: EIVT (up to Day 42), EOT (up to Day 42), Week 2 Follow-up

Number of Participants for Global Response for Baseline Risk Factors for Candidemia and Invasive Candidiasis: EIVT

Intervention	participants (Number)
	APACHE <20 (EIVT): Success	APACHE <20 (EIVT): Failure	APACHE ≥20 (EIVT): Success	APACHE ≥20 (EIVT): Failure	APACHE <20 (EOT): Success	APACHE <20 (EOT): Failure	APACHE ≥20 (EOT): Success	APACHE ≥20 (EOT): Failure	APACHE <20 (Week 2 F/U): Success	APACHE <20 (Week 2 F/U): Failure	APACHE ≥20 (Week 2 F/U): Success	APACHE ≥20 (Week 2 F/U): Failure
Anidulafungin-Voriconazole	24	11	2	7	25	10	1	8	20	15	1	8

Global response based on assessments of Clinical Success or Failure and Microbiological Success or Failure. Global response at EIVT was assessed for participants categorized with baseline risk factors for Candidemia and Invasive Candidiasis: ICU stay ≥ 4 days, mechanical ventilation, broad spectrum antibiotics (antibiotics), central venous (CV) catheter, total parental nutrition (TPN), dialysis, abdominal surgery, solid organ transplant, renal insufficiency, chemotherapy, pancreatitis, systemic steroids or immunosuppressives (Systemic steroids/immunos), neutropenic status, or elderly. (NCT00548262)
Timeframe: EIVT (up to Day 42)

Number of Participants for Global Response for Baseline Risk Factors for Candidemia and Invasive Candidiasis: Week 2 Follow-up

Intervention	participants (Number)
	ICU stay ≥ 4 days (Yes): Success	ICU stay ≥ 4 days (Yes): Failure	ICU stay ≥ 4 days (No): Success	ICU stay ≥ 4 days (No): Failure	Mechanical ventilation (Yes): Success	Mechanical ventilation (Yes): Failure	Mechanical ventilation (No): Success	Mechanical ventilation (No): Failure	Antibiotics (Yes): Success	Antibiotics (Yes): Failure	Antibiotics (No): Success	Antibiotics (No): Failure	CV Catheter (Yes): Success	CV Catheter (Yes): Failure	CV Catheter (No): Success	CV Catheter (No): Failure	TPN (Yes): Success	TPN (Yes): Failure	TPN (No): Success	TPN (No): Failure	Dialysis (Yes): Success	Dialysis (Yes): Failure	Dialysis (No): Success	Dialysis (No): Failure	Abdominal surgery (Yes): Success	Abdominal surgery (Yes): Failure	Abdominal surgery (No): Success	Abdominal surgery (No): Failure	Solid organ transplant (No): Success	Solid organ transplant (No): Failure	Renal insufficiency (Yes): Success	Renal insufficiency (Yes): Failure	Renal insufficiency (No): Success	Renal insufficiency (No): Failure	Chemotherapy (Yes): Success	Chemotherapy (Yes): Failure	Chemotherapy (No): Success	Chemotherapy (No): Failure	Pancreatitis (Yes): Success	Pancreatitis (Yes): Failure	Pancreatitis (No): Success	Pancreatitis (No): Failure	Systemic steroids/immunos (Yes): Success	Systemic steroids/immunos (Yes): Failure	Systemic steroids/immunos (No): Success	Systemic steroids/immunos (No): Failure	Neutropenic: Success	Neutropenic: Failure	Non-neutropenic: Success	Non-neutropenic: Failure
Anidulafungin-Voriconazole	18	14	8	4	18	15	8	3	22	17	4	1	21	17	5	1	6	7	20	11	3	4	23	14	12	7	14	11	26	18	3	4	23	14	1	0	25	18	2	3	24	15	7	5	19	13	2	1	18	11

Global response based on assessments of Clinical Success or Failure and Microbiological Success or Failure. Global response at Week 2 F/U was assessed for participants categorized with baseline risk factors for Candidemia and Invasive Candidiasis: ICU stay ≥ 4 days, mechanical ventilation, broad spectrum antibiotics (antibiotics), central venous (CV) catheter, total parental nutrition (TPN), dialysis, abdominal surgery, solid organ transplant, renal insufficiency, chemotherapy, pancreatitis, systemic steroids or immunosuppressives (Systemic steroids/immunos), neutropenic status, or elderly. (NCT00548262)
Timeframe: Baseline, Week 2 Follow-up (F/U)

Number of Participants for Global Response for Pre-specified Baseline Risk Factors Subgroups of Interest: EOT

Intervention	participants (Number)
	ICU stay ≥ 4 days (Yes): Success	ICU stay ≥ 4 days (Yes): Failure	ICU stay ≥ 4 days (No): Success	ICU stay ≥ 4 days (No): Failure	Mechanical ventilation (Yes): Success	Mechanical ventilation (Yes): Failure	Mechanical ventilation (No): Success	Mechanical ventilation (No): Failure	Antibiotics (Yes): Success	Antibiotics (Yes): Failure	Antibiotics (No): Success	Antibiotics (No): Failure	CV Catheter (Yes): Success	CV Catheter (Yes): Failure	CV Catheter (No): Success	CV Catheter (No): Failure	TPN (Yes): Success	TPN (Yes): Failure	TPN (No): Success	TPN (No): Failure	Dialysis (Yes): Success	Dialysis (Yes): Failure	Dialysis (No): Success	Dialysis (No): Failure	Abdominal surgery (Yes): Success	Abdominal surgery (Yes): Failure	Abdominal surgery (No): Success	Abdominal surgery (No): Failure	Solid organ transplant (No): Success	Solid organ transplant (No): Failure	Renal insufficiency (Yes): Success	Renal insufficiency (Yes): Failure	Renal insufficiency (No): Success	Renal insufficiency (No): Failure	Chemotherapy (Yes): Success	Chemotherapy (Yes): Failure	Chemotherapy (No): Success	Chemotherapy (No): Failure	Pancreatitis (Yes): Success	Pancreatitis (Yes): Failure	Pancreatitis (No): Success	Pancreatitis (No): Failure	Systemic steroids/immunos (Yes): Success	Systemic steroids/immunos (Yes): Failure	Systemic steroids/immunos (No): Success	Systemic steroids/immunos (No): Failure	Neutropenic: Success	Neutropenic: Failure	Non-neutropenic: Success	Non-neutropenic: Failure
Anidulafungin-Voriconazole	12	20	9	3	13	20	8	3	19	20	2	3	18	20	3	3	5	8	16	15	1	6	20	17	8	11	13	12	21	23	1	6	20	17	1	0	20	23	2	3	19	20	5	7	16	16	2	1	15	14

Global response based on assessments of Clinical Success or Failure and Microbiological Success or Failure. Global response at EOT was assessed for participants categorized with baseline risk factors (Yes or No status) for Intensive Care Unit (ICU) stay ≥ 4 days, mechanical ventilation, broad spectrum antibiotics (antibiotics), central venous (CV) catheter, total parental nutrition (TPN), dialysis, abdominal surgery, solid organ transplant, renal insufficiency, chemotherapy, pancreatitis, systemic steroids or immunosuppressives (Systemic steroids/immunos), neutropenic status, or elderly. (NCT00548262)
Timeframe: Baseline, EOT (up to Day 42)

Number of Participants for Global Response Per Type of Candida Species Isolated at Baseline: EIVT

Intervention	participants (Number)
	ICU stay ≥ 4 days (Yes): Success	ICU stay ≥ 4 days (Yes): Failure	ICU stay ≥ 4 days (No): Success	ICU stay ≥ 4 days (No): Failure	Mechanical ventilation (Yes): Success	Mechanical ventilation (Yes): Failure	Mechanical ventilation (No): Success	Mechanical ventilation (No): Failure	Antibiotics (Yes): Success	Antibiotics (Yes): Failure	Antibiotics (No): Success	Antibiotics (No): Failure	CV Catheter (Yes): Success	CV Catheter (Yes): Failure	CV Catheter (No): Success	CV Catheter (No): Failure	TPN (Yes): Success	TPN (Yes): Failure	TPN (No): Success	TPN (No): Failure	Dialysis (Yes): Success	Dialysis (Yes): Failure	Dialysis (No): Success	Dialysis (No): Failure	Abdominal surgery (Yes): Success	Abdominal surgery (Yes): Failure	Abdominal surgery (No): Success	Abdominal surgery (No): Failure	Solid organ transplant (No): Success	Solid organ transplant (No): Failure	Renal insufficiency (Yes): Success	Renal insufficiency (Yes): Failure	Renal insufficiency (No): Success	Renal insufficiency (No): Failure	Chemotherapy (Yes): Success	Chemotherapy (Yes): Failure	Chemotherapy (No): Success	Chemotherapy (No): Failure	Pancreatitis (Yes): Success	Pancreatitis (Yes): Failure	Pancreatitis (No): Success	Pancreatitis (No): Failure	Systemic steroids/immunos (Yes): Success	Systemic steroids/immunos (Yes): Failure	Systemic steroids/immunos (No): Success	Systemic steroids/immunos (No): Failure	Neutropenic: Success	Neutropenic: Failure	Non-neutropenic: Success	Non-neutropenic: Failure
Anidulafungin-Voriconazole	18	14	8	4	18	15	8	3	22	17	4	1	21	17	5	1	5	8	21	10	3	4	23	14	11	8	15	10	26	18	3	4	23	14	1	0	25	18	1	4	25	14	6	6	20	12	2	1	18	11

Number of Participants for Global Response Per Type of Candida Species Isolated at Baseline: EOT

Intervention	participants (Number)
	Candida albicans: Success	Candida albicans: Failure	Candida famata: Success	Candida famata: Failure	Candida glabrata: Success	Candida glabrata: Failure	Candida guilliermondii: Success	Candida guilliermondii: Failure	Candida krusei: Success	Candida krusei: Failure	Candida parapsilosis: Success	Candida parapsilosis: Failure	Candida pelliculosa: Success	Candida pelliculosa: Failure	Candida tropicalis: Success	Candida tropicalis: Failure	Unidentifiable: Success	Unidentifiable: Failure
Anidulafungin-Voriconazole	11	10	1	1	2	1	1	0	2	1	1	5	1	0	8	2	4	3

Number of Participants for Global Response Per Type of Candida Species Isolated at Baseline: Week 2 Follow-up

Number of Participants Per Survival Status (Alive or Dead) on Day 30

Number of Participants With Death Attributable (Yes or No) to Candidemia or Invasive Candidiasis

"Death is attributable to Candidemia or Invasive Candidiasis if investigator recorded disease under study as cause of death. Candidemia (positive blood culture) or Invasive Cadidiasis (yeast cells in histopathological or cytopathological exam). Week 6 Follow-up visit conducted by phone." (NCT00548262)
Timeframe: Baseline to Week 6 Follow-up

Medical Resource Utilization (MRU): Duration of Intensive Care Unit or Critical Care Unit Stay (Days)

Analysis of length of hospital stay based on Kaplan-Meier survival techniques. (NCT00496197)
Timeframe: Baseline up to 6 Week Follow-up (EOS)

Medical Resource Utilization (MRU): Duration of Intravenous Therapy (Days)

Analysis of length of hospital stay based on Kaplan-Meier survival techniques. (NCT00496197)
Timeframe: Baseline up to End of Intravenous treatment (Day 5 up to Day 28)

Medical Resource Utilization (MRU): Duration of Overall Therapy (Days)

Overall therapy includes Intravenous and Oral therapy. Participants were to receive at least 5 days and a maximum of 28 days of IV anidulafungin. After that, participants could continue treatment with oral fluconazole or voriconazole for at least 14 days from the day of last positive culture. (NCT00496197)
Timeframe: Baseline up to End of Treatment (Day 5 up to Day 42)

Number of Participants Who Died

(NCT00496197)
Timeframe: Baseline up to Week 6 Follow-up (EOS) or 30 days after last dose of study drug (whichever was later)

Time (75% Quartile Point Estimate) to Negative Blood and / or Tissue Culture for Candida Species

Participants with a negative culture on Day 1 were not included in the analysis. For participants with a positive culture on Day 1, the first day on which there was a negative culture was determined and then compared to the result of the next culture. If the next culture was also negative, or the next culture was positive but the interval between the 2 cultures was > 3 days, the earlier of the 2 cultures was the day of first negative blood culture. If next culture was positive and taken within 3 days of the previous culture, the process was repeated with the next negative blood culture. (NCT00496197)
Timeframe: Baseline (Day 1) up to Week 6 Follow-up (EOS)

Medical Resource Utilization (MRU): Duration of Hospital Stay (Days)

Measured as time to dischargeable (medically dischargeable status) and as time to discharge (actual discharge). Analysis of length of hospital stay based on Kaplan-Meier survival techniques. (NCT00496197)
Timeframe: Baseline up to 6 Week Follow-up (EOS)

Number of Participants Per Specified Cause of Death

Cause of death (includes all-cause and attributable to Candida infection) reported based on death due to Serious Adverse Events (SAEs). SAEs are any untoward medical occurrence at any dose that results in death, is life threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, results in congenital anomaly or birth defect. Participants may be counted with > 1 cause of death if multiple causes were present. (NCT00496197)
Timeframe: Baseline up to Week 6 Follow-up (EOS) or 30 days after last dose of study drug (whichever was later)

Number of Participants With Clinical Response at EOIV

Clinical Success=Cure: resolution of Candida s/s or Improvement: significant but incomplete resolution of s/s; Clinical Failure: at least 3 doses Anidulafungin with no significant improvement in s/s or death due to Candida. (NCT00496197)
Timeframe: End of Intravenous treatment (Day 5 up to Day 28)

Number of Participants With Clinical Response at EOT

Number of Participants With Global Response of Success or Failure (Based on Clinical and Microbiological Response) at End of Intravenous Treatment (EOIV)

Success: Clinical response=Cure (s/s of Candida) or Improvement (significant, incomplete resolution of s/s) and Microbiological response=Eradication (f/u culture negative) or Presumed Eradication (f/u culture n/a and response of clinical success). Failure: Clinical response=Failure (≥3 doses Anidulafungin with no significant improvement in s/s or death due to Candida) and Microbiological response=Persistence (positive culture for ≥1 baseline Candida spp) or Presumed Persistence (f/u culture n/a and clinical outcome= failure). (NCT00496197)
Timeframe: End of Intravenous treatment (Day 5 up to Day 28)

Number of Participants With Global Response of Success or Failure (Based on Clinical and Microbiological Response) at End of Treatment (EOT)

Success: Clinical response=Cure (no signs, symptoms [s/s] of Candida) or Improvement (significant, incomplete resolution of s/s) and Microbiological response=Eradication (follow up [f/u] culture negative) or Presumed Eradication (f/u culture not available [n/a] and response of clinical success). Failure: Clinical response=Failure (≥3 doses Anidulafungin with no significant improvement in s/s or death due to Candida) and Microbiological response=Persistence (positive culture for ≥1 baseline Candida species [spp]) or Presumed Persistence (f/u culture n/a and clinical outcome= failure). (NCT00496197)
Timeframe: End of Treatment (Day 5 up to Day 42)

Number of Participants With Global Response of Success or Failure (Based on Clinical and Microbiological Response) at EOIV for Participants With Non-albicans Candida at Baseline

Number of Participants With Global Response of Success or Failure (Based on Clinical and Microbiological Response) at EOT for Participants With Non-albicans Candida at Baseline

Number of Participants With Global Response of Success or Failure (Based on Clinical and Microbiological Response) at Week 2 Follow-up for Participants With Non-albicans Candida at Baseline

Number of Participants With Global Response of Success or Failure (Based on Clinical and Microbiological Response) at Week 6 Follow-up (EOS) for Participants With Non-albicans Candida at Baseline

Number of Participants With Microbiological Response at EOIV

Microbiological Success=Eradication: negative culture for baseline Candida spp or Presumed Eradication: f/u culture n/a and clinical outcome defined as success (cure or improvement); Microbiological Failure=Persistence: positive culture for at least 1 baseline Candida spp or Presumed Persistence: f/u culture n/a and clinical outcome defined as failure (≥3 doses Anidulafungin with no significant improvement in s/s or death due to Candida). (NCT00496197)
Timeframe: End of Intravenous treatment (Day 5 up to Day 28)

Number of Participants With Microbiological Response at EOT

Number of Participants With Non-serious and Serious Adverse Events

AEs are any untoward medical occurrence in a clinical investigation subject administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. SAEs are any untoward medical occurrence at any dose that results in death, is life threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, results in congenital anomaly or birth defect. (NCT00496197)
Timeframe: Baseline up to Week 6 Follow-up (EOS) or 30 days after last dose of study drug (whichever was later)

Number of Participants With Sustained (Continued) Clinical Response at Week 2 Follow-up

Number of Participants With Sustained (Continued) Clinical Response at Week 6 Follow-up (EOS)

Number of Participants With Sustained (Continued) Global Response of Success or Failure (Based on Clinical and Microbiological Response) at Week 2 Follow-up

Number of Participants With Sustained (Continued) Global Response of Success or Failure (Based on Clinical and Microbiological Response) at Week 6 Follow-up (End of Study [EOS])

Number of Participants With Sustained (Continued) Microbiological Response at Week 2 Follow-up

Number of Participants With Sustained (Continued) Microbiological Response at Week 6 Follow-up (EOS)

Number of Subjects With Global Response of Success at End of Treatment

Number of subjects with clinician assessed global response of success; defined as cure (resolution of signs and symptoms of Candida infection) or improvement (significant but incomplete resolution of signs and symptoms of Candida infection) on the clinical response in conjunction with eradication (follow up negative culture result for Candida species [spp]) or presumed eradication (follow up culture was not available and clinical outcome defined as success) on the microbiological response. (NCT00537329)
Timeframe: End of treatment (EOT) = Day 5 up to Day 42

Absolute Values for β-D-glucan Assay Results at Endpoints in Relation to Clinical Response Status of Success or Status of Failure at End of All Treatment

Absolute values for β-D-glucan (range 0 to 6000 picograms per milliliter [pg/mL]) summarized at all timeframe endpoints by subject's at end of all treatment clinical response status of success (Success at EOT) or failure (Failure at EOT) and as combined status of all subjects (All at EOT). Success: cure (resolution of signs and symptoms of Candida infection) or improvement (significant but incomplete resolution of signs and symptoms); failure: no significant improvement in signs and symptoms or death due to Candida infection; subjects must have received at least 3 doses of anidulafungin. (NCT00537329)
Timeframe: Baseline, Day 3, Day 5, Day 7, EOT (Day 5 up to Day 42)

Absolute Values for β-D-glucan Assay Results at Endpoints in Relation to Microbiological Response Status of Success or Status of Failure at End of All Treatment

Absolute values for β-D-glucan (range 0 to 6000 pg/mL) summarized at timeframe endpoints by subject's at end of all treatment microbiological response status of Success at EOT or Failure at EOT and as combined status of All at EOT. Success: eradication (follow up negative culture for Candida spp) or presumed eradication (follow up culture was not available and clinical outcome defined as success); failure: persistence (follow up culture was positive for at least 1 baseline Candida spp) or presumed persistence (follow up culture was not available and clinical outcome was defined as failure). (NCT00537329)
Timeframe: Baseline, Day 3, Day 5, Day 7, EOT (Day 5 up to Day 42)

Change From Baseline for β-D-glucan Assay Results at Endpoints in Relation to Clinical Response Status of Success or Status of Failure at End of All Treatment

Change from baseline for β-D-glucan (range 0 to 6000 pg/mL) summarized at endpoints by subject's at end of all treatment clinical response status of Success at EOT or Failure at EOT and as combined status of All at EOT. Success=cure (resolution of signs, symptoms of Candida infection) or improvement (significant but incomplete resolution of signs, symptoms); failure=no significant improvement or death due to Candida infection; subject must have received at least 3 doses of anidulafungin. Percent change calculated as ([mean value of β-D-glucan at observation-baseline value]/baseline value*100). (NCT00537329)
Timeframe: Baseline, Day 3, Day 5, Day 7, EOT (Day 5 up to Day 42)

Change From Baseline for β-D-glucan Assay Results at Endpoints in Relation to Microbiological Response of Status of Success or Status of Failure at EOT

Change from baseline in β-D-glucan (range 0 to 6000 pg/mL) summarized at endpoints and by subject's EOT microbiological response status of Success at EOT or Failure at EOT and as combined status of All at EOT. Success=eradication (negative culture Candida spp or presumed eradication (culture not available, clinical outcome defined as success); failure=persistence (culture positive for at least 1 baseline Candida spp) or presumed persistence (culture not available, clinical outcome defined as failure). Percent change=([mean value of β-D-glucan at observation-baseline value]/baseline value*100). (NCT00537329)
Timeframe: Baseline, Day 3, Day 5, Day 7, EOT (Day 5 up to Day 42)

Number of Subjects With Clinical Response of Success at Endpoints

Number of subjects with clinician assessed clinical response (CR) of success. Defined as cure or improvement (cure/improvement): cure=resolution of signs and symptoms of Candida infection; improvement=significant but incomplete resolution of signs and symptoms of Candida infection on the clinical response. (NCT00537329)
Timeframe: EOIT, EOT (Day 5 up to Day 42), 2 Wks post EOT, 6 Wks post EOT, 12 Wks post baseline

Number of Subjects With Global Response of Success at Endpoints

Number of subjects with clinician assessed global response of success. Defined as cure or improvement (cure/improvement): cure=resolution of signs and symptoms of Candida infection; improvement=significant but incomplete resolution of signs and symptoms of Candida infection on the clinical response in conjunction with eradication or presumed eradication (erad/presumed erad): erad=follow up negative culture result for Candida spp; presumed erad=follow up culture was not available and clinical outcome defined as success on the microbiological response. (NCT00537329)
Timeframe: End of intravenous treatment (EOIT), end of Week 2 after EOT (2 Wks post EOT), end of Week 6 after EOT (6 Wks post EOT), at end of 12 weeks after baseline (12 Wks post baseline)

Number of Subjects With Global Response of Success at EOT in Relation to Subject Subgroups

Number of subjects with clinician assessed global response of success at EOT (clinical=cure, improvement, microbiological=eradication, presumed eradication) in relation to subject subgroups (subject may be represented in >1 subgroup). Subgroups: Neutropenic status (absolute neutrophil count [ANC in cubic millimeters [cmm]); baseline pathogen; previous surgery (any surgery, abdominal surgery); organ transplantation (kidney, liver, heart); elderly; renal insufficiency (calculated creatinine clearance [CCC] in milliliters per minute [mL/min]); central venous catheter; receiving chemotherapy. (NCT00537329)
Timeframe: EOT (Day 5 up to Day 42)

Number of Subjects With Microbiological Response of Success at Endpoints

Number of subjects with clinician assessed microbiological response (MR) of success. Defined as eradication or presumed eradication (erad/presumed erad): erad=follow up negative culture result for Candida spp; presumed eradication=follow up culture was not available and clinical outcome defined as success on the microbiological response. (NCT00537329)
Timeframe: EOIT, EOT (Day 5 up to Day 42), 2 Wks post EOT, 6 Wks post EOT, 12 Wks post baseline

Intervention	days (Mean)
	Time to dischargeable	Time to discharge
Anidulafungin	27.3	27.1

Intervention	participants (Number)
	Acute myocardial infarction	Acute respiratory failure	Anastomotic complication	Ascites	Atrial flutter	Bile duct cancer	Brain oedema	Cardiac arrest	Cardiac failure congestive	Cardio-respiratory arrest	Chronic hepatic failure	Coagulopathy	Colon cancer	Convulsion	Deep vein thrombosis	Diabetes mellitus	Disease progression	Dyspnoea	Electromechanical dissociation	Endocarditis	Endotracheal intubation	Fungaemia	Gastrointestinal haemorrhage	Gastrointestinal ischaemia	General physical health deterioration	Haemorrhage	Haemorrhage intracranial	Hepatic failure	Hypoglycaemia	Hyponatraemia	Hypotension	Infection	Ischaemic cardiomyopathy	Liver function test abnormal	Lymphoma	Mental status changes	Metastatic gastric cancer	Multi-organ disorder	Multi-organ failure	Multiple myeloma	Multiple sclerosis relapse	Myocardial infarction	Neoplasm malignant	Peritonitis	Peritonitis bacterial	Pneumonia	Pneumothorax	Pulmonary embolism	Pulmonary haemorrhage	Renal failure	Renal failure acute	Renal failure chronic	Respiratory arrest	Respiratory distress	Respiratory failure	Sepsis	Septic shock	Systemic candida	Thrombocytopenia	Wound dehiscence
Anidulafungin	1	1	1	2	1	1	1	5	1	1	2	1	1	1	1	1	8	1	1	1	1	1	1	1	1	1	1	1	2	1	2	1	1	1	3	1	1	1	4	1	1	1	1	1	1	3	1	1	1	5	1	1	3	2	6	12	7	1	1	1

Intervention	participants (Number)
	Attributable death (Yes)	Attributable death (No)
Anidulafungin-Voriconazole	4	19

Intervention	participants (Number)
	Eradication	Presumed eradication	Persistence	Presumed persistence
Anidulafungin	163	61	15	3

Intervention	participants (Number)
	Non-serious Adverse Events	Serious Adverse Events
Anidulafungin	216	134

Intervention	pg/mL (Mean)
	Success at EOT: baseline β-D-glucan (n=30)	Failure at EOT: baseline β-D-glucan (n=10)	All at EOT: baseline β-D-glucan (n=40)	Success at EOT: Day 3 β-D-glucan (n=32)	Failure at EOT: Day 3 β-D-glucan (n=4)	All at EOT: Day 3 β-D-glucan (n=36)	Success at EOT: Day 5 β-D-glucan (n=29)	Failure at EOT: Day 5 β-D-glucan (n=6)	All at EOT: Day 5 β-D-glucan (n=35)	Success at EOT: Day 7 β-D-glucan (n=24)	Failure at EOT: Day 7 β-D-glucan (n=4)	All at EOT: Day 7 β-D-glucan (n=28)	Success at EOT: EOT β-D-glucan (n=28)	Failure at EOT: EOT β-D-glucan (n=3)	All at EOT: EOT β-D-glucan (n=31)
Anidulafungin	1095.8	1447.9	1183.9	1132.0	2753.3	1312.1	1140.5	2443.8	1363.9	1190.8	3140.8	1469.4	1018.9	2917.7	1202.7

Intervention	pg/mL (Mean)
	Success at EOT: baseline β-D-glucan (n=32)	Failure at EOT: baseline β-D-glucan (n=8)	All at EOT: baseline β-D-glucan (n=40)	Success at EOT: Day 3 β-D-glucan (n=32)	Failure at EOT: Day 3 β-D-glucan (n=4)	All at EOT: Day 3 β-D-glucan (n=36)	Success at EOT: Day 5 β-D-glucan (n=29)	Failure at EOT: Day 5 β-D-glucan (n=6)	All at EOT: Day 5 β-D-glucan (n=35)	Success at EOT: Day 7 β-D-glucan (n=24)	Failure at EOT: Day 7 β-D-glucan (n=4)	All at EOT: Day 7 β-D-glucan (n=28)	Success at EOT: EOT β-D-glucan (n=31)	All at EOT: EOT β-D-glucan (n=31)
Anidulafungin	1219.7	1040.4	1183.9	1349.0	1017.4	1312.1	1444.3	975.3	1363.9	1527.2	1122.3	1469.4	1202.7	1202.7

Intervention	percent change (Mean)
	Success at EOT: Day 3 β-D-glucan (n=30)	Failure at EOT: Day 3 β-D-glucan (n=4)	All at EOT: Day 3 β-D-glucan (n=34)	Success at EOT: Day 5 β-D-glucan (n=27)	Failure at EOT: Day 5 β-D-glucan (n=6)	All at EOT: Day 5 β-D-glucan (n=33)	Success at EOT: Day 7 β-D-glucan (n=23)	Failure at EOT: Day 7 β-D-glucan (n=4)	All at EOT: Day 7 β-D-glucan (n=27)	Success at EOT: EOT β-D-glucan (n=27)	Failure at EOT: EOT β-D-glucan (n=3)	All at EOT: EOT β-D-glucan (n=30)
Anidulafungin	-0.4	-11.0	-1.7	-1.0	1.3	-0.6	4.3	4.5	4.3	7.0	14.0	7.7

Intervention	participants (Number)
	EOIT: success (cure/improvement)	EOIT: cure	EOIT: improvement	EOT: success (cure/improvement)	EOT: cure	EOT: improvement	2 Wks post EOT: success (cure/improvement)	2 Wks post EOT: cure	2 Wks post EOT: improvement	6 Wks post EOT: success (cure/improvement)	6 Wks post EOT: cure	6 Wks post EOT: improvement	12 Wks post baseline: success (cure/improvement)	12 Wks post baseline: cure	12 Wks post baseline: improvement
Anidulafungin	34	27	7	32	27	5	26	25	1	17	16	1	17	17	0

Intervention	participants (Number)
	EOIT	2 Wks post EOT	6 Wks post EOT	12 Wks post baseline
Anidulafungin	33	24	17	16

Intervention	participants (Number)
	Neutropenic status: ANC ≤ 500/cmm (n=2)	Neutropenic status: ANC >500/cmm (n=37)	Baseline pathogen: Candida albicans (n=14)	Baseline pathogen: Candida glabrata (n=6)	Baseline pathogen: Candida parapsilosis (n=4)	Baseline pathogen: Candida rugosa (n=1)	Baseline pathogen: Candida tropicalis (n=18)	Previous surgery: Any surgery (n=13)	Previous surgery: Abdominal surgery (n=8)	Elderly: Age ≥ 65 years (n=17)	Renal insufficiency (CCC < 30 mL/min) (n=11)	Use of Central venous catheter = Yes (n=21)	Receiving chemotherapy = Yes (n=7)
Anidulafungin	1	28	10	4	4	1	13	11	7	10	6	17	5

Intervention	participants (Number)
	EOIT: success (erad/presumed erad)	EOIT: erad	EOIT: presumed erad	EOT: success (erad/presumed erad)	EOT: erad	EOT: presumed erad	2 Wks post EOT: success (erad/presumed erad)	2 Wks post EOT: erad	2 Wks post EOT: presumed erad	6 Wks post EOT: success (erad/presumed erad)	6 Wks post EOT: erad	6 Wks post EOT: presumed erad	12 Wks post baseline: success (erad/presumed erad)	12 Wks post baseline: erad	12 Wks post baseline: presumed erad
Anidulafungin	36	31	5	34	31	3	25	22	3	17	14	3	16	14	2

Article	Year
Epidemiology of candidemia in NICE area, France: A five-year study of antifungal susceptibility and mortality. Journal de mycologie medicale, 2022, Volume: 32, Issue:1 Topics: Antifungal Agents; Candida; Candidemia; Drug Resistance, Fungal; Fluconazole; Humans; Microbial Sens	2022
Prevalence of biofilms in Candida spp. bloodstream infections: A meta-analysis. PloS one, 2022, Volume: 17, Issue:2 Topics: Biofilms; Candida; Candidemia; Candidiasis; Caspofungin; Drug Resistance, Fungal; Fluconazole; Hospi	2022
Worldwide emergence of fluconazole-resistant Candida parapsilosis: current framework and future research roadmap. The Lancet. Microbe, 2023, Volume: 4, Issue:6 Topics: Adult; Antifungal Agents; Azoles; Candida parapsilosis; Candidemia; Fluconazole; Humans; Infant, New	2023
European confederation of medical mycology quality of clinical candidaemia management score: A review of the points based best practice recommendations. Mycoses, 2021, Volume: 64, Issue:2 Topics: Antifungal Agents; Blood Culture; Candida; Candidemia; Candidiasis; Central Venous Catheters; Echino	2021
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies. Clinical drug investigation, 2021, Volume: 41, Issue:6 Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl	2021
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies. Clinical drug investigation, 2021, Volume: 41, Issue:6 Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl	2021
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies. Clinical drug investigation, 2021, Volume: 41, Issue:6 Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl	2021
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies. Clinical drug investigation, 2021, Volume: 41, Issue:6 Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl	2021
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies. Clinical drug investigation, 2021, Volume: 41, Issue:6 Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl	2021
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies. Clinical drug investigation, 2021, Volume: 41, Issue:6 Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl	2021
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies. Clinical drug investigation, 2021, Volume: 41, Issue:6 Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl	2021
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies. Clinical drug investigation, 2021, Volume: 41, Issue:6 Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl	2021
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies. Clinical drug investigation, 2021, Volume: 41, Issue:6 Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl	2021
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies. Clinical drug investigation, 2021, Volume: 41, Issue:6 Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl	2021
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies. Clinical drug investigation, 2021, Volume: 41, Issue:6 Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl	2021
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies. Clinical drug investigation, 2021, Volume: 41, Issue:6 Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl	2021
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies. Clinical drug investigation, 2021, Volume: 41, Issue:6 Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl	2021
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies. Clinical drug investigation, 2021, Volume: 41, Issue:6 Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl	2021
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies. Clinical drug investigation, 2021, Volume: 41, Issue:6 Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl	2021
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies. Clinical drug investigation, 2021, Volume: 41, Issue:6 Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl	2021
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies. Clinical drug investigation, 2021, Volume: 41, Issue:6 Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl	2021
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies. Clinical drug investigation, 2021, Volume: 41, Issue:6 Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl	2021
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies. Clinical drug investigation, 2021, Volume: 41, Issue:6 Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl	2021
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies. Clinical drug investigation, 2021, Volume: 41, Issue:6 Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl	2021
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies. Clinical drug investigation, 2021, Volume: 41, Issue:6 Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl	2021
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies. Clinical drug investigation, 2021, Volume: 41, Issue:6 Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl	2021
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies. Clinical drug investigation, 2021, Volume: 41, Issue:6 Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl	2021
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies. Clinical drug investigation, 2021, Volume: 41, Issue:6 Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl	2021
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies. Clinical drug investigation, 2021, Volume: 41, Issue:6 Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl	2021
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies. Clinical drug investigation, 2021, Volume: 41, Issue:6 Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl	2021
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies. Clinical drug investigation, 2021, Volume: 41, Issue:6 Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl	2021
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies. Clinical drug investigation, 2021, Volume: 41, Issue:6 Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl	2021
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies. Clinical drug investigation, 2021, Volume: 41, Issue:6 Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl	2021
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies. Clinical drug investigation, 2021, Volume: 41, Issue:6 Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl	2021
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies. Clinical drug investigation, 2021, Volume: 41, Issue:6 Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl	2021
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies. Clinical drug investigation, 2021, Volume: 41, Issue:6 Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl	2021
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies. Clinical drug investigation, 2021, Volume: 41, Issue:6 Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl	2021
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies. Clinical drug investigation, 2021, Volume: 41, Issue:6 Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl	2021
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies. Clinical drug investigation, 2021, Volume: 41, Issue:6 Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl	2021
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies. Clinical drug investigation, 2021, Volume: 41, Issue:6 Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl	2021
Deciphering the epidemiology of invasive candidiasis in the intensive care unit: is it possible? Infection, 2021, Volume: 49, Issue:6 Topics: Candida; Candidemia; Candidiasis, Invasive; Drug Resistance, Fungal; Echinocandins; Fluconazole; Hum	2021
Comparison of mortality between echinocandins and polyenes for an initial treatment of candidemia: A systematic review and meta-analysis. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2021, Volume: 27, Issue:11 Topics: Antifungal Agents; Candidemia; Echinocandins; Fluconazole; Humans; Polyenes	2021
Are Journal of clinical microbiology, 2018, Volume: 56, Issue:12 Topics: Animals; Antifungal Agents; Azoles; Candida; Candidemia; Fluconazole; Humans; Microbial Sensitivity	2018
Molecular characterization and antifungal susceptibility testing of Candida nivariensis from blood samples - an Iranian multicentre study and a review of the literature. Journal of medical microbiology, 2019, Volume: 68, Issue:5 Topics: Adolescent; Aged; Amphotericin B; Amplified Fragment Length Polymorphism Analysis; Antifungal Agents	2019
Background changing patterns of neonatal fungal sepsis in a developing country. Journal of tropical pediatrics, 2013, Volume: 59, Issue:6 Topics: Antifungal Agents; Birth Weight; Candida; Candidemia; Candidiasis; Drug Resistance, Fungal; Female;	2013
Candida and candidaemia. Susceptibility and epidemiology. Danish medical journal, 2013, Volume: 60, Issue:11 Topics: Amphotericin B; Antifungal Agents; Candida; Candidemia; Denmark; Echinocandins; Fluconazole; Humans;	2013
Fungal prophylaxis in neonates: a review article. Advances in neonatal care : official journal of the National Association of Neonatal Nurses, 2014, Volume: 14, Issue:1 Topics: Administration, Intravenous; Administration, Oral; Amphotericin B; Antifungal Agents; Aspergillosis;	2014
Is Fluconazole or an Echinocandin the Agent of Choice for Candidemia. The Annals of pharmacotherapy, 2015, Volume: 49, Issue:9 Topics: Adult; Aged; Antifungal Agents; Candida; Candidemia; Cost-Benefit Analysis; Cross Infection; Disease	2015
Complications of Candidemia in ICU Patients: Endophthalmitis, Osteomyelitis, Endocarditis. Seminars in respiratory and critical care medicine, 2015, Volume: 36, Issue:5 Topics: Amphotericin B; Antifungal Agents; Candida; Candidemia; Echinocandins; Echocardiography; Endocarditi	2015
Epidemiology of candidemia and antifungal susceptibility in invasive Candida species in the Asia-Pacific region. Future microbiology, 2016, Volume: 11 Topics: Anidulafungin; Antifungal Agents; Asia; Azoles; Candida; Candida albicans; Candida glabrata; Candida	2016
Treatment of candidemia in adult patients without neutropenia--an inconvenient truth. Critical care (London, England), 2011, Volume: 15, Issue:1 Topics: Adult; Amphotericin B; Animals; Antifungal Agents; Candidemia; Echinocandins; Fluconazole; Fungal Pr	2011
The role of fluconazole in the treatment of Candida endocarditis: a meta-analysis. Medicine, 2011, Volume: 90, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antifungal Agents; Candida albicans; Candidemia; Candidiasis; Dose-R	2011
Candida infections in non-neutropenic children after the neonatal period. Expert review of anti-infective therapy, 2011, Volume: 9, Issue:10 Topics: Amphotericin B; Antifungal Agents; Candida; Candidemia; Catheter-Related Infections; Child; Cross In	2011
Occurrence, presentation and treatment of candidemia. Expert review of clinical immunology, 2012, Volume: 8, Issue:8 Topics: Antifungal Agents; Candida; Candidemia; Drug Resistance, Fungal; Echinocandins; Fluconazole; Humans;	2012

Article	Year
Anidulafungin for the treatment of candidaemia caused by Candida parapsilosis: Analysis of pooled data from six prospective clinical studies. Mycoses, 2017, Volume: 60, Issue:10 Topics: Administration, Intravenous; Adult; Anidulafungin; Antifungal Agents; Azoles; Candida parapsilosis;	2017
Anidulafungin for the treatment of candidaemia caused by Candida parapsilosis: Analysis of pooled data from six prospective clinical studies. Mycoses, 2017, Volume: 60, Issue:10 Topics: Administration, Intravenous; Adult; Anidulafungin; Antifungal Agents; Azoles; Candida parapsilosis;	2017
Anidulafungin for the treatment of candidaemia caused by Candida parapsilosis: Analysis of pooled data from six prospective clinical studies. Mycoses, 2017, Volume: 60, Issue:10 Topics: Administration, Intravenous; Adult; Anidulafungin; Antifungal Agents; Azoles; Candida parapsilosis;	2017
Anidulafungin for the treatment of candidaemia caused by Candida parapsilosis: Analysis of pooled data from six prospective clinical studies. Mycoses, 2017, Volume: 60, Issue:10 Topics: Administration, Intravenous; Adult; Anidulafungin; Antifungal Agents; Azoles; Candida parapsilosis;	2017
Anidulafungin for the treatment of candidaemia caused by Candida parapsilosis: Analysis of pooled data from six prospective clinical studies. Mycoses, 2017, Volume: 60, Issue:10 Topics: Administration, Intravenous; Adult; Anidulafungin; Antifungal Agents; Azoles; Candida parapsilosis;	2017
Anidulafungin for the treatment of candidaemia caused by Candida parapsilosis: Analysis of pooled data from six prospective clinical studies. Mycoses, 2017, Volume: 60, Issue:10 Topics: Administration, Intravenous; Adult; Anidulafungin; Antifungal Agents; Azoles; Candida parapsilosis;	2017
Anidulafungin for the treatment of candidaemia caused by Candida parapsilosis: Analysis of pooled data from six prospective clinical studies. Mycoses, 2017, Volume: 60, Issue:10 Topics: Administration, Intravenous; Adult; Anidulafungin; Antifungal Agents; Azoles; Candida parapsilosis;	2017
Anidulafungin for the treatment of candidaemia caused by Candida parapsilosis: Analysis of pooled data from six prospective clinical studies. Mycoses, 2017, Volume: 60, Issue:10 Topics: Administration, Intravenous; Adult; Anidulafungin; Antifungal Agents; Azoles; Candida parapsilosis;	2017
Anidulafungin for the treatment of candidaemia caused by Candida parapsilosis: Analysis of pooled data from six prospective clinical studies. Mycoses, 2017, Volume: 60, Issue:10 Topics: Administration, Intravenous; Adult; Anidulafungin; Antifungal Agents; Azoles; Candida parapsilosis;	2017
Anidulafungin for the treatment of candidaemia caused by Candida parapsilosis: Analysis of pooled data from six prospective clinical studies. Mycoses, 2017, Volume: 60, Issue:10 Topics: Administration, Intravenous; Adult; Anidulafungin; Antifungal Agents; Azoles; Candida parapsilosis;	2017
Anidulafungin for the treatment of candidaemia caused by Candida parapsilosis: Analysis of pooled data from six prospective clinical studies. Mycoses, 2017, Volume: 60, Issue:10 Topics: Administration, Intravenous; Adult; Anidulafungin; Antifungal Agents; Azoles; Candida parapsilosis;	2017
Anidulafungin for the treatment of candidaemia caused by Candida parapsilosis: Analysis of pooled data from six prospective clinical studies. Mycoses, 2017, Volume: 60, Issue:10 Topics: Administration, Intravenous; Adult; Anidulafungin; Antifungal Agents; Azoles; Candida parapsilosis;	2017
Anidulafungin for the treatment of candidaemia caused by Candida parapsilosis: Analysis of pooled data from six prospective clinical studies. Mycoses, 2017, Volume: 60, Issue:10 Topics: Administration, Intravenous; Adult; Anidulafungin; Antifungal Agents; Azoles; Candida parapsilosis;	2017
Anidulafungin for the treatment of candidaemia caused by Candida parapsilosis: Analysis of pooled data from six prospective clinical studies. Mycoses, 2017, Volume: 60, Issue:10 Topics: Administration, Intravenous; Adult; Anidulafungin; Antifungal Agents; Azoles; Candida parapsilosis;	2017
Anidulafungin for the treatment of candidaemia caused by Candida parapsilosis: Analysis of pooled data from six prospective clinical studies. Mycoses, 2017, Volume: 60, Issue:10 Topics: Administration, Intravenous; Adult; Anidulafungin; Antifungal Agents; Azoles; Candida parapsilosis;	2017
Anidulafungin for the treatment of candidaemia caused by Candida parapsilosis: Analysis of pooled data from six prospective clinical studies. Mycoses, 2017, Volume: 60, Issue:10 Topics: Administration, Intravenous; Adult; Anidulafungin; Antifungal Agents; Azoles; Candida parapsilosis;	2017
Anidulafungin for the treatment of candidaemia caused by Candida parapsilosis: Analysis of pooled data from six prospective clinical studies. Mycoses, 2017, Volume: 60, Issue:10 Topics: Administration, Intravenous; Adult; Anidulafungin; Antifungal Agents; Azoles; Candida parapsilosis;	2017
Anidulafungin for the treatment of candidaemia caused by Candida parapsilosis: Analysis of pooled data from six prospective clinical studies. Mycoses, 2017, Volume: 60, Issue:10 Topics: Administration, Intravenous; Adult; Anidulafungin; Antifungal Agents; Azoles; Candida parapsilosis;	2017
Anidulafungin for the treatment of candidaemia caused by Candida parapsilosis: Analysis of pooled data from six prospective clinical studies. Mycoses, 2017, Volume: 60, Issue:10 Topics: Administration, Intravenous; Adult; Anidulafungin; Antifungal Agents; Azoles; Candida parapsilosis;	2017
Anidulafungin for the treatment of candidaemia caused by Candida parapsilosis: Analysis of pooled data from six prospective clinical studies. Mycoses, 2017, Volume: 60, Issue:10 Topics: Administration, Intravenous; Adult; Anidulafungin; Antifungal Agents; Azoles; Candida parapsilosis;	2017
Anidulafungin for the treatment of candidaemia caused by Candida parapsilosis: Analysis of pooled data from six prospective clinical studies. Mycoses, 2017, Volume: 60, Issue:10 Topics: Administration, Intravenous; Adult; Anidulafungin; Antifungal Agents; Azoles; Candida parapsilosis;	2017
Anidulafungin for the treatment of candidaemia caused by Candida parapsilosis: Analysis of pooled data from six prospective clinical studies. Mycoses, 2017, Volume: 60, Issue:10 Topics: Administration, Intravenous; Adult; Anidulafungin; Antifungal Agents; Azoles; Candida parapsilosis;	2017
Anidulafungin for the treatment of candidaemia caused by Candida parapsilosis: Analysis of pooled data from six prospective clinical studies. Mycoses, 2017, Volume: 60, Issue:10 Topics: Administration, Intravenous; Adult; Anidulafungin; Antifungal Agents; Azoles; Candida parapsilosis;	2017
Anidulafungin for the treatment of candidaemia caused by Candida parapsilosis: Analysis of pooled data from six prospective clinical studies. Mycoses, 2017, Volume: 60, Issue:10 Topics: Administration, Intravenous; Adult; Anidulafungin; Antifungal Agents; Azoles; Candida parapsilosis;	2017
Anidulafungin for the treatment of candidaemia caused by Candida parapsilosis: Analysis of pooled data from six prospective clinical studies. Mycoses, 2017, Volume: 60, Issue:10 Topics: Administration, Intravenous; Adult; Anidulafungin; Antifungal Agents; Azoles; Candida parapsilosis;	2017
Anidulafungin for the treatment of candidaemia caused by Candida parapsilosis: Analysis of pooled data from six prospective clinical studies. Mycoses, 2017, Volume: 60, Issue:10 Topics: Administration, Intravenous; Adult; Anidulafungin; Antifungal Agents; Azoles; Candida parapsilosis;	2017
Anidulafungin for the treatment of candidaemia caused by Candida parapsilosis: Analysis of pooled data from six prospective clinical studies. Mycoses, 2017, Volume: 60, Issue:10 Topics: Administration, Intravenous; Adult; Anidulafungin; Antifungal Agents; Azoles; Candida parapsilosis;	2017
Anidulafungin for the treatment of candidaemia caused by Candida parapsilosis: Analysis of pooled data from six prospective clinical studies. Mycoses, 2017, Volume: 60, Issue:10 Topics: Administration, Intravenous; Adult; Anidulafungin; Antifungal Agents; Azoles; Candida parapsilosis;	2017
Anidulafungin for the treatment of candidaemia caused by Candida parapsilosis: Analysis of pooled data from six prospective clinical studies. Mycoses, 2017, Volume: 60, Issue:10 Topics: Administration, Intravenous; Adult; Anidulafungin; Antifungal Agents; Azoles; Candida parapsilosis;	2017
Anidulafungin for the treatment of candidaemia caused by Candida parapsilosis: Analysis of pooled data from six prospective clinical studies. Mycoses, 2017, Volume: 60, Issue:10 Topics: Administration, Intravenous; Adult; Anidulafungin; Antifungal Agents; Azoles; Candida parapsilosis;	2017
Anidulafungin for the treatment of candidaemia caused by Candida parapsilosis: Analysis of pooled data from six prospective clinical studies. Mycoses, 2017, Volume: 60, Issue:10 Topics: Administration, Intravenous; Adult; Anidulafungin; Antifungal Agents; Azoles; Candida parapsilosis;	2017
Anidulafungin for the treatment of candidaemia caused by Candida parapsilosis: Analysis of pooled data from six prospective clinical studies. Mycoses, 2017, Volume: 60, Issue:10 Topics: Administration, Intravenous; Adult; Anidulafungin; Antifungal Agents; Azoles; Candida parapsilosis;	2017
Anidulafungin for the treatment of candidaemia caused by Candida parapsilosis: Analysis of pooled data from six prospective clinical studies. Mycoses, 2017, Volume: 60, Issue:10 Topics: Administration, Intravenous; Adult; Anidulafungin; Antifungal Agents; Azoles; Candida parapsilosis;	2017
Anidulafungin for the treatment of candidaemia caused by Candida parapsilosis: Analysis of pooled data from six prospective clinical studies. Mycoses, 2017, Volume: 60, Issue:10 Topics: Administration, Intravenous; Adult; Anidulafungin; Antifungal Agents; Azoles; Candida parapsilosis;	2017
Anidulafungin for the treatment of candidaemia caused by Candida parapsilosis: Analysis of pooled data from six prospective clinical studies. Mycoses, 2017, Volume: 60, Issue:10 Topics: Administration, Intravenous; Adult; Anidulafungin; Antifungal Agents; Azoles; Candida parapsilosis;	2017
Anidulafungin for the treatment of candidaemia caused by Candida parapsilosis: Analysis of pooled data from six prospective clinical studies. Mycoses, 2017, Volume: 60, Issue:10 Topics: Administration, Intravenous; Adult; Anidulafungin; Antifungal Agents; Azoles; Candida parapsilosis;	2017
Evaluation of an early step-down strategy from intravenous anidulafungin to oral azole therapy for the treatment of candidemia and other forms of invasive candidiasis: results from an open-label trial. BMC infectious diseases, 2014, Feb-21, Volume: 14 Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Anidulafungin; An	2014
Ocular manifestations of candidemia. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2011, Aug-01, Volume: 53, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amphotericin B; Antifungal Agents; Candida; Candidemia;	2011
Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: support for the 2009 IDSA treatment guidelines for candidiasis. Critical care (London, England), 2011, Volume: 15, Issue:5 Topics: Aged; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Double-Blind Method; Echi	2011